


Regulation (EU) No 528/2012 concerning the making available on the market and use of biocidal products

PRODUCT ASSESSMENT REPORT OF A BIOCIDAL PRODUCT FOR NATIONAL AUTHORISATION APPLICATIONS



AUTAN KIDS SPRAY

Product type 19

Ethyl butylacetylaminopropionate
(Further referred to as IR3535®)

Case Number in R4BP: BC-BL013906-42

Case Number in R4BP: BC-SV082132-13

Evaluating Competent Authority: FRANCE

Date: 05/2022

Updated date: 11/2023

TABLE OF CONTENTS

TABLE OF CONTENTS.....	2
0 DOSSIER'S HISTORY	6
1 CONCLUSION.....	8
2 CONCLUSION : NA-MIC 2023.....	8
3 ASSESSMENT REPORT	9
3.1 SUMMARY OF THE PRODUCT ASSESSMENT	9
3.1.1 <i>Administrative information</i>	9
3.1.1.1 Identifier of the product	9
3.1.1.2 Authorisation holder	9
3.1.1.3 Manufacturer(s) of the products	9
3.1.1.4 Manufacturer(s) of the active substance	9
3.1.2 <i>Product composition and formulation</i>	10
3.1.2.1 Identity of the active substance	10
3.1.2.2 Candidate(s) for substitution.....	10
3.1.2.3 Qualitative and quantitative information on the composition of the biocidal product	10
3.1.2.4 Information on technical equivalence	10
3.1.2.5 Information on the substance(s) of concern	10
3.1.2.6 Type of formulation	11
3.1.3 <i>Hazard and precautionary statements</i>	12
3.1.4 <i>Authorised use(s)</i>	13
3.1.4.1 Use description	13
3.1.4.2 Use-specific instructions for use	13
3.1.4.3 Use-specific risk mitigation measures.....	14
3.1.4.4 Where specific to the use, the particulars of likely direct or indirect effects, first aid instructions and emergency measures to protect the environment	14
3.1.4.5 Where specific to the use, the instructions for safe disposal of the product and its packaging	15
3.1.4.6 Where specific to the use, the conditions of storage and shelf-life of the product under normal conditions of storage	15
3.1.5 <i>General directions for use</i>	15
3.1.5.1 Instructions for use	15
3.1.5.2 Risk mitigation measures	15
3.1.5.3 Particulars of likely direct or indirect effects, first aid instructions and emergency measures to protect the environment	15
3.1.5.4 Instructions for safe disposal of the product and its packaging	15
3.1.5.5 Conditions of storage and shelf-life of the product under normal conditions of storage	15
3.1.6 <i>Other information</i>	15
3.1.7 <i>Packaging of the biocidal product</i>	16
3.1.8 <i>Documentation</i>	17

3.1.8.1	Data submitted in relation to product application.....	17
3.1.8.2	Access to documentation.....	17
3.2	ASSESSMENT OF THE BIOCIDAL PRODUCT	18
3.2.1	<i>Intended use(s) as applied for by the applicant.....</i>	18
3.2.2	<i>Clarification on product composition and compositions tested</i>	18
3.2.3	<i>Physical, chemical and technical properties.....</i>	20
3.2.4	<i>Physical hazards and respective characteristics</i>	28
3.2.5	<i>Methods for detection and identification</i>	30
3.2.6	<i>Efficacy against target organisms</i>	33
3.2.6.1	Function and field of use	33
3.2.6.2	Organisms to be controlled and products, organisms or objects to be protected	33
3.2.6.3	Effects on target organisms, including unacceptable suffering	34
3.2.6.4	Mode of action, including time delay	34
3.2.6.5	Efficacy data	35
3.2.6.6	Occurrence of resistance and resistance management.....	37
3.2.6.7	Known limitations.....	37
3.2.6.8	Evaluation of the label claims.....	37
3.2.6.9	Relevant information if the product is intended to be authorised for use with other biocidal product(s).....	38
3.2.7	<i>Risk assessment for human health</i>	39
3.2.7.1	Assessment of effects on Human Health	39
(I)	<i>Skin corrosion and irritation.....</i>	39
(II)	<i>Eye Irritation</i>	41
(III)	<i>Respiratory tract irritation</i>	43
(IV)	<i>Skin sensitization</i>	44
(V)	<i>Respiratory sensitization (ADS).....</i>	45
(VI)	<i>Acute toxicity.....</i>	47
(VII)	<i>Information on dermal absorption.....</i>	50
(VIII)	<i>Available toxicological data relating to non active substance(s) (i.e. substance(s) of concern)</i>	51
(IX)	<i>Available toxicological data relating to a mixture</i>	51
(X)	<i>Other.....</i>	51
3.2.7.2	Exposure assessment.....	52
(I)	<i>General information</i>	53
(II)	<i>List of scenarios</i>	55
(III)	<i>Industrial exposure.....</i>	56
(IV)	<i>Professional exposure</i>	56
(V)	<i>Non-professional exposure</i>	57
(VI)	<i>Exposure of the general public</i>	66
(VII)	<i>Monitoring data</i>	67
(VIII)	<i>Dietary exposure.....</i>	67

(IX) Exposure associated with production, formulation and disposal of the biocidal product	68
(X) Aggregated exposure	69
(XI) Summary of exposure assessment.....	70
3.2.7.3 Risk characterisation for human health.....	72
Reference values to be used in Risk Characterisation.....	72
(I) Risk for industrial users.....	73
(II) Risk for professional users	73
(III) Risk for non-professional users.....	74
(IV) Risk for the general public	77
(V) Risk for consumers via residues in food	77
(VI) Risk characterisation from combined exposure to several active substances or substances of concern within a biocidal product.....	77
3.2.8 Risk assessment for animal health.....	77
3.2.9 Risk assessment for the environment.....	78
3.2.9.1 Effects assessment on the environment.....	78
Environmental fate and behavior of the active substance	78
Effect assessment of the active substance.....	79
(I) Information relating to the ecotoxicity of the biocidal product which is sufficient to enable a decision to be made concerning the classification of the product is required	80
(II) Further Ecotoxicological studies.....	80
(III) Effects on any other specific, non-target organisms (flora and fauna) believed to be at risk (ADS).....	80
(IV) Supervised trials to assess risks to non-target organisms under field conditions	80
(V) Studies on acceptance by ingestion of the biocidal product by any non-target organisms thought to be at risk	80
(VI) Secondary ecological effect e.g. when a large proportion of a specific habitat type is treated (ADS)	80
(VII) Foreseeable routes of entry into the environment on the basis of the use envisaged	80
(VIII) Further studies on fate and behaviour in the environment (ADS).....	81
(IX) Leaching behaviour (ADS)	81
(X) Testing for distribution and dissipation in soil (ADS).....	81
(XI) Testing for distribution and dissipation in water and sediment (ADS)	81
(XII) Testing for distribution and dissipation in air (ADS).....	81
(XIII) If the biocidal product is to be sprayed near to surface waters then an overspray study may be required to assess risks to aquatic organisms or plants under field conditions (ADS).....	81
(XIV) If the biocidal product is to be sprayed outside or if potential for large scale formation of dust is given then data on overspray behaviour may be required to assess risks to bees and non-target arthropods under field conditions (ADS).....	81
3.2.9.2 Exposure assessment.....	82
(I) General information	82

(II)	<i>Emission estimation</i>	83
(III)	<i>Fate and distribution in exposed environmental compartments</i>	87
(IV)	<i>Calculated PEC values</i>	88
(V)	<i>Primary and secondary poisoning</i>	88
3.2.9.3	<i>Risk characterisation</i>	89
(I)	<i>Atmosphere</i>	89
(II)	<i>Sewage treatment plant (STP)</i>	89
(III)	<i>Aquatic compartment</i>	89
(IV)	<i>Terrestrial compartment</i>	89
(V)	<i>Groundwater</i>	90
(VI)	<i>Primary and secondary poisoning</i>	90
(VII)	<i>Mixture toxicity</i>	90
3.2.10	<i>Measures to protect man, animals and the environment</i>	91
3.2.11	<i>Assessment of a combination of biocidal products</i>	91
3.2.12	<i>Comparative assessment</i>	91
4	ANNEXES	92
4.1	LIST OF STUDIES FOR THE BIOCIDAL PRODUCT.....	92
4.2	OUTPUT TABLES FROM EXPOSURE ASSESSMENT TOOLS	93
4.2.1	<i>Human exposure calculations</i>	93
4.3	NEW INFORMATION ON THE ACTIVE SUBSTANCE	93
4.4	RESIDUE BEHAVIOUR.....	93
4.5	SUMMARIES OF THE EFFICACY STUDIES (B.5.10.1-XX).....	93
4.6	CONFIDENTIAL ANNEX	93
4.7	OTHER	93

Overview of applications

Overview regarding all relevant applications

Application type	refMS	Case number in the refMS	Decision date	Assessment carried out
NA-APP	BE	BC-BL013906-42	16/05/2017	First authorisation
NA-AAT	BE	BC-AF044421-66	26/10/2018	Amendment by eCA (dissemination)
NA-AAT	BE	BC-DK051391-49	10/05/2019	Amendment by eCA*
NA-AAT	BE	BC-DV053441-28	19/08/2019	Amendment by eCA (Amendment to correct the access levels to PAR-documents)
NA-AAT	BE	BC-RM075307-20	23/05/2022	Amendment by eCA of the PAR (section 2.2.4) following MRS – condition of authorisation and SPC no change.

* COMMISSION IMPLEMENTING DECISION (EU) 2018/1477 of 2 October 2018: product authorization for Insect Repellent Pump Spray IR3535 20% (Asset nr.: BE-0012319-0000) is amended to eliminate discrepancy for application rates used for efficacy, human health and environmental risk assessment. The final PAR contains revised terms and conditions of the authorization after re-evaluation.

0 DOSSIER'S HISTORY

Note to the reader

The product AUTAN SPRAY KIDS is a Same Product as the reference product, INSECT REPELLENT PUMP SPRAY IR3535® 20%, for which an authorization was granted by Belgium competent authorities on 16th of May 2017 (case number:BC-BL013906-42).

Thus, this document is based on the PAR of the INSECT REPELLENT PUMP SPRAY IR3535® 20%. Only the administrative sections were adapted in this document to be in line with the information provided for AUTAN SPRAY KIDS.

This consolidated PAR for the **minor** change application of the product AUTAN KIDS SPRAY is based on the PAR of the authorisation of the product INSECT REPELLENT PUMP SPRAY IR3535® 20%, in which all necessary addenda have been included. Each section contains the initial assessment and the subsequent successive assessments (minor change, major change, post authorisation data...) the assessments related to the minor change of the product are at the end of each section and are highlighted in grey.

In part 2.1 of the updated PAR the “proposal for decision” corresponds to the summary of product characteristics related to the updated decision.

Note that in the whole document the name of the product is still INSECT REPELLENT PUMP SPRAY IR3535® 20%, as it is the reference product for the same application.

History of the dossier

Application type	refMS/eCA	Case number in the refMS	Decision date	Assessment carried out (i.e. first authorisation / amendment / renewal)	Chapter/ page
NA-APP	MSCA-Belgium	BC-BL013906-42	16.05.2017	Initial assessment	
NA-MRP	MSCA-France	BC-UW020009-14	17.04.2019	Mutual recognition in parallel	
NA-AAT	MSCA-France	BC-FV064020-35	18.01.2021	Amendment of national authorisation	
NA-BBS	MSCA-France	BC-AM073927-25	05.04.2022	National authorisation of same biocidal product (authorised)	
NA-MIC	MSCA-France	BC-SV082132-13	27.11.2023	Increase of the shelf-life from 18 months to 2 years	

1 CONCLUSION

Insect Repellent Pump Spray IR3535® 20% can be authorized following Art.19(1) of Regulation (EU) No 528/2012 as a ready-to-use repellent (PT19) to be used against mosquitoes and ticks in temperate areas and should only be applied once per day on uncovered parts of the face, hands, arms, legs and feet.

Within two years of the publication by the European Chemicals Agency of Union guidance on how to generate efficacy data for insect repellents at the recommended application rates, the authorization holder shall submit data to confirm the minimum effective application rate. Those data shall be submitted in the form of an application for a change of the authorization in accordance with Commission Implementing Regulation (EU) No 354/2013.

Remark:

- This product is not authorized for use on children below 1 year old.
- This product is not authorized for use in tropical conditions, due to lack of efficacy studies.
- This product is not authorized for use on clothes, due to lack of efficacy studies
- This product is not authorized to be used against biting flies (stable flies, black flies, sand flies), deer flies, biting midges, house flies, wasps and bees, due to lack of efficacy studies

2 CONCLUSION

NA-MIC minor change application 2023

Minor change description:

- Increase of the self-life from 18 months to 2 years

➤ **Physico chemical properties and analytical methods minor change**

A new storage stability study (24 months at ambient temperature) has been provided. The test item showed no major modification after 24 months at ambient temperature. Spaying data have also been submitted before and after storage.

The results show that the product remains stable after a storage of 24 months. The satisfactory operation of the trigger sprayer has also been demonstrated before and after storage.

Therefore, a shelf-life of 2 years can be granted for the product.

3 ASSESSMENT REPORT

3.1 SUMMARY OF THE PRODUCT ASSESSMENT

3.1.1 Administrative information

3.1.1.1 Identifier of the product

Identifier	Country (if relevant)
AUTAN KIDS SPRAY AUTAN DEFENSE TOUT-PETITS SPRAY AUTAN DEFENSE PEDIATRICS SPRAY AUTAN DEFENSE LITTLE KIDS SPRAY	FRANCE

3.1.1.2 Authorisation holder

Name and address of the authorisation holder	Name	SC JOHNSON EUROPE SARL
	Address	Z.A la Piece 8 1180 – Rolle Switzerland
Authorisation number	BC-SV082132-13	
Date of the authorisation	05.04.2023	
Expiry date of the authorisation		

3.1.1.3 Manufacturer(s) of the products

Name of manufacturer	SC JOHNSON EUROPE SARL
Address of manufacturer	Z.A la Piece 8 1180 – Rolle Switzerland
Location of manufacturing sites	S.C. Johnson Europlant B.V., Groot Mijdrechtstraat 81, 3641 RV Mijdrecht Netherlands

3.1.1.4 Manufacturer(s) of the active substance

Active substance	Ethyl butylacetylaminopropionate
Name of manufacturer	Merck S.L.U.
Address of manufacturer	Calle Maria de Molina 40 28006 Madrid Spain
Location of manufacturing sites	Poligono Merck 08100 Mollet de Vallés Barcelona Spain
Name of manufacturer	Merck KGaA
Address of manufacturer	Frankfurter Straße 250 64293 Darmstadt Germany
Location of manufacturing sites	Poligono Merck 08100 Mollet de Vallés Barcelona Spain

3.1.2 Product composition and formulation


NB: the full composition of the product according to Annex III Title 1 should be provided in the confidential annex.

Does the product have the same identity and composition as the product evaluated in connection with the approval for listing of the active substance(s) on the Union list of approved active substances under Regulation No. 528/2012?

Yes

No

3.1.2.1 Identity of the active substance

Main constituent(s)	
ISO name	IR3535
IUPAC or EC name	ethyl 3-[N-acetyl-N-butyl] aminopropionate
EC number	257-835-0
CAS number	52304-36-6
Index number in Annex VI of CLP	
Minimum purity / content	≥ 99 % w/w
Structural formula	

3.1.2.2 Candidate(s) for substitution

The active substance IR3535[®] is not a candidate for substitution.

3.1.2.3 Qualitative and quantitative information on the composition of the biocidal product

Common name	IUPAC name	Function	CAS number	EC number	Content (%)
IR3535 [®]	ethyl 3-[N-acetyl-N-butyl] aminopropionate	Active substance	52304-36-6	257-835-0	20 purity: ≥99%

Full composition is available in the confidential annex.

3.1.2.4 Information on technical equivalence

Not needed, since the manufacturer is the same as included in the Union list of approved active substances.

3.1.2.5 Information on the substance(s) of concern

The biocidal product contains the following substances of concern (SoC):

Common name	IUPAC name	Function	CAS number	EC number	Content (%)
Ethanol 96%	Ethanol	Solvent	64-17-5	200-578-6	35

During the referral discussions concerning this product, it was decided that ethanol should be considered as a substance of concern (SoC).

According to the definition in the BPR (Article (3)(f)), a SoC is a substance which has an inherent capacity to cause an adverse effect. In this product, ethanol is the cause for the classification as a flammable liquid and during the referral discussions it was agreed that flammability can be considered as a cause to provoke an adverse effect and, therefore, ethanol should be considered as a SoC.

Due to the lack of guidance in relation to physical-chemical endpoints, the methodology described in the guidance for human health assessment of SoC, can be applied by analogy. Accordingly, the label of the product should include the corresponding H/P statements but a qualitative/quantitative risk assessment is not necessary. Ethanol will be indicated in the SPC Section 2.1.

Related to the submission of the analytical method for determining the concentration of the SoC, Article 21 of the BPR is applicable and waiving of the data requirements is allowed and accepted.

3.1.2.6 Type of formulation

AL – Any other liquid

3.1.3 Hazard and precautionary statements

Classification and labelling of the products of the family according to the Regulation (EC) 1272/2008

Classification	
Hazard category	Flammable liquid, category 3 Eye irritation, category 2
Hazard statement	H226: Flammable liquid and vapour H319: Causes serious eye irritation
Labelling	
Signal words	Warning
Hazard statements	H226: Flammable liquid and vapour H319: Causes serious eye irritation
Precautionary statements	P101 If medical advice is needed, have product container or label at hand P102 Keep out of reach of children. P210 Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking P264 Wash hands thoroughly after handling P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P337 + P313: If eye irritation persists: Get medical advice/attention. P501 Dispose of contents/container in accordance with local/regional/national/international regulations
Note	

3.1.4 Authorised use(s)

3.1.4.1 Use description

Table 1. Use # 1 – Spray to repel mosquitoes and ticks from human skin (general public)		
Product Type	PT19 – Repellents and attractants (Pest control)	
Where relevant, an exact description of the authorised use	Repellent	
Target organism (including development stage)	Scientific name	Common name
	Culicidae	Mosquitoes
	Ixodidae	Ticks
	only in temperate areas	
Field of use	<p>Use indoors only in well ventilated areas and outdoors</p> <p>AUTAN KIDS SPRAY is a ready-to-use insect repellent used to protect humans against mosquitoes and ticks in temperate areas <u>only</u>. The product is not intended to be used in tropical areas. The product is only suitable for adults and children older than 1 year.</p> <p>The repellent is sprayed onto the skin, only on uncovered parts of the face, hands, arms, legs and feet.</p>	
Application method(s)	Spray directly onto the exposed skin and distribute the liquid on the skin by hand.	
Application rate(s) and frequency	<p>Apply sparingly to uniformly cover uncovered parts of the face, hands, arms, legs and feet.</p> <p>Dose per application:</p> <ul style="list-style-type: none"> • adult: 6.12 g or approx. 53 sprays • child (between 6 and 12 years): 3.39 g or approx. 29 sprays • child (between 2 and 6 years): 2.51 g or approx. 21 sprays • toddler (between 1 and 2 years): 1.77 g or approx. 15 sprays <p>Protection time:</p> <ul style="list-style-type: none"> • against mosquitoes: up to 8 hours • against ticks: up to 12 hours <p>AUTAN KIDS SPRAY is intended to be used in summer when insects are frequent. It can only be applied once a day. The product is suitable only for children older than 1 year.</p>	
Category(ies) of users	General public	
Pack sizes and packaging material	Type	Material
	Bottle	Plastic: HDPE
	Size	≥25.0 - ≤ 750.0 mL

3.1.4.2 Use-specific instructions for use

Apply the product evenly onto exposed skin and distribute the applied spray liquid on the skin by hand. ONLY apply to uncovered parts of the body, limited to arms, hands, legs, feet and face.

Do not spray directly on the face. For treatment of the face, spray the repellent solution onto the palm of the hand and distribute the solution over the skin of the face thereby taking care to protect the eyes. Do not spray into the eyes or apply to eye area.

An adult should apply the product to children below 12 years of age. Do not use on children's hands. Do not apply over cuts, wounds, freshly shaven or irritated skin. Do not use under clothing. Only for external use.

Only children older than 1 year can use this product. Caution must be taken when using these products on children. Use products very responsibly. Mechanical protection (clothing, mosquito nets) is to be preferred at all times.

Avoid contact with synthetic materials. Synthetic materials should be protected during spraying.

Applying sun care products or cosmetic formulations after repellent use will decrease the efficacy of the repellent considerably.

The product is not intended for use on animals/pets.

3.1.4.3 Use-specific risk mitigation measures

Use repellent safely. Always read the label and product information before use.

Suitable only for children older than 1 year.

Keep out of reach of children.

Avoid breathing spray. Do not spray directly on the face.

Use only outdoors or in a well-ventilated area.

ONLY apply to uncovered parts of the face, hands, arms, legs and feet. Do not use under clothing.

Mechanical protection (clothing, mosquito nets) is to be preferred at all times. Only for external use. Use only as directed.

The users should inform if the treatment is ineffective and report straightforward to the registration holder.

3.1.4.4 Where specific to the use, the particulars of likely direct or indirect effects, first aid instructions and emergency measures to protect the environment

Causes serious eye irritation.

After inhalation: fresh air.

After eye contact: rinse out with plenty of water. Call in ophthalmologist.

After swallowing: immediately make victim drink water (two glasses at most). Consult a physician.

Most important symptoms and effects, both acute and delayed: irritant effects

Indication of any immediate medical attention and special treatment needed: No information available

Personal precautions, protective equipment and emergency procedures

Advice for non-emergency personnel: Do not breathe vapours, aerosols. Avoid substance contact. Ensure adequate ventilation. Evacuate the danger area, observe emergency procedures, consult an expert.

Environmental precautions: Do not discharge superfluous fluids to the drain.

3.1.4.5 Where specific to the use, the instructions for safe disposal of the product and its packaging

Waste material must be disposed of in accordance with the Directive on waste 2008/98/EC as well as other national and local regulations. Leave chemicals in original containers. No mixing with other waste. Handle uncleaned containers like the product itself.
Do not discharge superfluous fluids to the drain.

3.1.4.6 Where specific to the use, the conditions of storage and shelf-life of the product under normal conditions of storage

Storage conditions: Keep container tightly closed in a dry and well-ventilated place. Keep away from heat and sources of ignition.

The product should not be stored for prolonged times at temperatures >40°C.

Shelf-life: 2 years

Advice on safe handling: Observe label precautions. Keep away from open flames, hot surfaces and sources of ignition. Take precautionary measures against static discharge.

Environmental exposure controls: Do not let product enter drains.

3.1.5 General directions for use

There is only one authorised used. All directions can be found in the use-specific section.

3.1.5.1 Instructions for use

See §2.1.4.2

3.1.5.2 Risk mitigation measures

See §2.1.4.3

3.1.5.3 Particulars of likely direct or indirect effects, first aid instructions and emergency measures to protect the environment

See §2.1.4.4

3.1.5.4 Instructions for safe disposal of the product and its packaging

See §2.1.4.5

3.1.5.5 Conditions of storage and shelf-life of the product under normal conditions of storage

See §2.1.4.6

3.1.6 Other information

N.A.

3.1.7 Packaging of the biocidal product

Type of packaging	Size/volume of the packaging	Material of the packaging	Type and material of closure(s)	Intended user (e.g. professional, non-professional)	Compatibility of the product with the proposed packaging materials (Yes/No)
Bottle	≥25 - ≤750 mL	plastic: HDPE	Pump head covered by a cap made of PP and PE	non-professional	Yes

3.1.8 Documentation

3.1.8.1 Data submitted in relation to product application

Please see §3.1 list of studies for the biocidal product.

3.1.8.2 Access to documentation

The applicant of this product is the same as the review programme participant for the active substance and is thus the owner of all data on the active substance.

3.2 ASSESSMENT OF THE BIOCIDAL PRODUCT

3.2.1 Intended use(s) as applied for by the applicant

Table 2. Use # 1 – Application to skin			
Product Type	PT19 – Repellents and attractants (Pest control)		
Where relevant, an exact description of the authorised use	AUTAN KIDS SPRAY is a ready to use product. The repellent is sprayed onto the skin. 3g product is sufficient for the application to approximately 50% of the body surface (face, hands, arms and legs as assessed in the CAR for IR3535®). For treatment of the face, spray the repellent solution onto the palm of the hand and distribute the solution over the skin of the face thereby taking care to protect the eyes. Relevant codes: VI.1.1 and VI.9 (manual distribution over skin)		
Target organism (including development stage)	Scientific name	Common name	Development stage
	Culicidae	Mosquitoes	Adults
	Ixodidae	Ticks	Nymphs
	Ixodidae	Ticks	Adults
Field of use	Other use in well ventilated areas		
Application method(s)	Spraying: The ready to use product is a pump spray which is sprayed directly onto the exposed skin		
Application rate(s) and frequency	Dose: 3.0 g AUTAN KIDS SPRAY is intended to be used in summer when insects are frequent. It is usually applied once a day depending on outdoor activities, weather and presence of insects. The application can be repeated when necessary (noticeable reduction in repellence). The pump spray can be applied up to 3 times per day for adults, up to 2 times for children between the age of 3 and 10 years and maximally 1 time per day for children below 3 years.		
Category(ies) of users	General public		
Pack sizes and packaging material	Type	Material	Size
	Bottle	Plastic: HDPE	>25.0 - < 750.0 mL
	Due to a technical issue with SPC-editor and IUCLID, the applicant wasn't able to include the \geq and \leq symbols. The applied packaging should have been 'larger or equal to 25 mL to smaller or equal to 750 mL'.		

3.2.2 Clarification on product composition and compositions tested

In the studies submitted several test materials were used. Below, the differences to the product Insect Repellent Pump Spray IR3535® 20% are described, whereas the full composition of the test materials is provided in the confidential part of the PAR.

- **Insect Repellent Pump Spray IR3535® 20% (= AUTAN KIDS SPRAY)**
- **Insect Repellent Pump Spray IR3535® 20% without Bitrex**
- **US Pump Spray Formulation:** In the US EPA formulation, ethanol denatured with Bitrex and tertbutanol (final concentrations 0.0002% and 0.042 %, respectively) is used, whereas in the EU formulation (Insect Repellent Pump Spray IR3535® 20%) a final concentration of 0.0011% Bitrex is present. Other components are identical in both formulations and only the water content was adjusted to compensate for the slight differences in composition.

- **Insect Repellent Pump Spray Lice IR3535® 20% without Bitrex:** Slightly higher concentration emollient, no film forming substance present, and no Bitrex present.
- **TMT-003** (efficacy test against *Aedes albopictus*): Similar to the Insect Repellent Pump Spray IR3535® 20% once dried on the skin. The 2-propanol and water will have evaporated and the remaining substances are present in the same concentration as the pump spray. The main difference is that TMT-003 also contains butylene glycol.

3.2.3 Physical, chemical and technical properties

Property	Guideline and Method	Purity of the test substance (% (w/w))	Results	Reference
Physical state at 25 °C and 101.3 kPa	OPPTS 830.6317 Storage Stability	US Pump Spray Formulation	Liquid	Study no 245-003, Meinerling M., 2009
Colour at 25 °C and 101.3 kPa	OPPTS 830.6317 Storage Stability / Organoleptic	US Pump Spray Formulation	Slightly yellowish to colourless	Study no 245-003, Meinerling M., 2009
Odour at 25 °C and 101.3 kPa	OPPTS 830.6317 Storage Stability / Organoleptic	US Pump Spray Formulation	Mild, slightly alcoholic	Study no 245-003, Meinerling M., 2009
Acidity / alkalinity	CIPAC MT75 At 20°C	US Pump Spray Formulation	Undiluted: between 4.4 and 5 At 1% : between 3.8 and 4.6	Study no 245-003, Meinerling M., 2009
Relative density / bulk density	OECD Guideline 109	US Pump Spray Formulation	Relative density D420 = 0.955	Study no 213-002, Fieseler A., 2011
Storage stability test – accelerated storage	CIPAC MT 46.3, under GLP regulation – HPLC method and Organoleptic	READ ACROSS Insect Repellent Pump Spray Lice IR3535® 20% without Bitrex	8 weeks at 40±2°C. Humidity 30-65%. Packaging: HDPE pump spray bottle – 150 mL - No change in colour, odour, or clarity. - No change in packaging appearance. -19.3% to 18.8%: this corresponds to a variation of 2.59% of active substance content - Free acid content: <0.5 % w/w before and after storage	31232204, Meinerling, M., 2009. Institut für Biologische Analytik und Consulting IBACON GmbH
Storage stability test – long term storage at ambient temperature	OPPTS 830.6317 Storage Stability	US Pump Spray Formulation	Packaging: commercial packaging: white HDPE flask	Study no 245-003, Meinerling M., 2009

Property	Guideline and Method	Purity of the test substance (% (w/w))	Results	Reference
			<p>with white pump stopper and clear cap</p> <ul style="list-style-type: none"> - No change in colour or clarity of the tested item. - No change in packaging appearance: no indication of corrosion or decomposition, no alteration of label -pH values (20°C): Undiluted formulation: 5.0 at the beginning of the test; 4.4 at the end of the test 1% dilution; 4.6 at the beginning of the test; 3.8 at the end of the test -Active substance content: 24 months at 25° : 20.1% to 17.9%: this corresponds to a variation of 10.9% of active substance content At 18 month : 20.1% to 19.1%: this corresponds to a variation of 5% of active substance content → results not acceptable for storage of 2 years but acceptable for 18 months. 	

Property	Guideline and Method	Purity of the test substance (% (w/w))	Results	Reference
			-Free acid content: At the beginning 0.1 % w/w; after 18 months of storage: 1.3% w/w; after 24 months of storage: 2.1%w/w	
Storage stability test – low temperature stability test for liquids	CIPAC MT 39.3	Insect Repellent Pump Spray IR3535® 20% without Bitrex	0°C during 1 week: colourless clear homogenous liquid with a slight alcoholic odour before and after.	Study no 245-010, Meinerling M., 2011
Effects on content of the active substance and technical characteristics of the biocidal product - light	-	US Pump Spray Formulation	The product is stored in lightproof plastic flasks → waived	Study no 245-003, Meinerling M., 2009
Effects on content of the active substance and technical characteristics of the biocidal product – temperature and humidity	organoleptic	US Pump Spray Formulation	Since the product is tightly closed there are no effects due to humidity. Effects of temperature have been studied (see above). The product should not be stored for prolonged times (more than 8 weeks) at temperatures >40°C.	Study no 245-003, Meinerling M., 2009
Effects on content of the active substance and technical characteristics of the biocidal product - reactivity towards container material	organoleptic	US Pump Spray Formulation	No indication of corrosion or decomposition was observed.	Study no 245-003, Meinerling M., 2009
Wettability	Waived	-	the product is liquid	-
Suspensibility, spontaneity and dispersion stability	Waived	-	the product is not intended to be diluted	-
Wet sieve analysis and dry sieve test	Waived	-	the product is not intended to be diluted and the product is liquid	-
Emulsifiability, re-emulsifiability and emulsion stability	Waived	-	the product is not intended to be diluted and is not an emulsion	-
Disintegration time	Waived	-	the product is not a tablet to be desintegrated	-
Particle size distribution, content of dust/fines, attrition, friability	Waived	-	the product is not a powder nor a granule	-

Property	Guideline and Method	Purity of the test substance (% (w/w))	Results	Reference
Persistent foaming	Waived	-	the product is not intended to be diluted	-
Flowability/Pourability/Dustability	Waived	-	the product is not a powder, a granule nor an emulsion	-
Burning rate – smoke generators	Waived	-	the product is not a smoke generator	-
Burning completeness – smoke generators	Waived	-	the product is not a smoke generator	-
Composition of smoke – smoke generators	Waived	-	the product is not a smoke generator	-
Spraying pattern	Waived	-	the product is not an aerosol	
	Particle size distribution [Laser light diffraction, technical compliance to the requirements of	Insect Repellent Pump Spray IR3535® 20%	Fraction of particles <5µm: <0.6 %. Range (n=50): 0.28 - 0.68 microns, with a mean of 0.45 % < 5.23 microns. Fraction of particles <50µm: 51.79<x<60.27 % Range (n=50): 47.78 – 54.86 microns, with respective means of 59.95 % and 51.46 %. [Malvern SprayTec Spectrometer, Distance nozzle to beam center: 3cm, Focal length: 200mm, Test time 200ms, Data recording rate: 1000Hz, Optical parameters: 1.34/0/1, Laser wave length: 670nm] Fraction of particles <10µm: ~1.5 %.	Study no 2016_04_26, B. Batz, 2016

Property	Guideline and Method	Purity of the test substance (% (w/w))	Results	Reference
			Range (n=12): 0.98 – 1.95%, with an average of 1.495 % <10 microns. [Malvern SprayTec Spectrometer, Focal length: 300mm, Test time 400ms, Data recording rate: 2.5kHz, Laser wave length: 632.8nm]	
Physical compatibility	Waived	-	the product is not intended to be used in combination with other products	-
Chemical compatibility	Waived	-	the product is not intended to be used in combination with other products	-
Degree of dissolution and dilution stability	Waived	-	the product is not a tablet and is not intended to be diluted	-
Surface tension	OECD 115	Insect Repellent Pump Spray IR3535® 20%	Surface tension of undiluted product = 29.581 mN/m (at 20°C)	Study no 009093, J. zur Lage, 2016
Viscosity	OECD 114 (rotational viscosimeter)	Insect Repellent Pump Spray IR3535® 20%	Viscosity (20°C) = 6.8 mPa.s Viscosity(40°C) = 3.46 mPa.s	Study no 009093, J. zur Lage, 2016 Lab investigation 009093 – PM-PFC-RT, zur Lage (04.07.2016) : IR3535_Ref Formulations Surface tension Viscosity_reg.Aff

➤ NA-MIC minor change application (2023)

Property	Guideline and Method	Purity of the test substance (% (w/w))	Results						Reference
Storage stability test – long term storage at ambient temperature	<p>Technical Monograph No. 17, 2nd Edition, Guidelines for Specifying the Shelf Life of Plant Protection Products, June 2009</p> <p>Analytical methods for IR3535 and IR3535 free acid reported in section 3.2.5</p>	Insect Repellent Pump Spray IR3535® 20% (EUS-26-15)	<p>The product has been stored during 24 months at ambient temperature in commercial packaging.</p> <p>The following parameters were tested:</p>						Andrea Fieseler, 2022 Study No: 152041228
			Test	T0	6 months	12 months	18 months	24 months	
			packaging	100 mL pump plastic bottle	No change	No change	No change	No change	
			appearance	Colourless liquid with an alcoholic odour	No change	No change	No change	No change	
			weight	-	-0.1%	-0.1%	-0.2%	-0.2%	
			Content of IR3535 (%w/w)	19.9	19.4 (-2.3%)	20.4 (+2.5%)	19.9	19.7 (-0.8%)	
			Content of IR3535 free acid (%w/w)	< 0.025	-	< 0.025	-	0.045	
			pH 1% suspension	6.9	5.4	5.3	4	4.9	
			pH undiluted	6.5	6	6	5.4	5.7	
			<p>The test item showed no major modification after 24 months at ambient temperature. However, the product is intended to be sold with a spray trigger and spraying data should be assessed before and after storage. This should include the spray pattern, the amount of spray delivered with each operation, observations on the nozzle for blockages and the MMAD.</p>						

<p>Spraying data</p>	<p>FEA method 644 (Filled Aerosols Packs – Evaluation of Aerosol Spray Patterns)</p>	<p>Insect Repellent Pump Spray IR3535® 20% (EUS-26-15)</p> <p>Sprayer reference: SILGAN Dispensing Systems Hemer GmbH, MK VII Max 0.18ml, Inverted, GPI 20-410 Compact Head</p>	<p>Spray pattern before and after storage of 24 months:</p> <table border="1" data-bbox="952 231 1877 486"> <thead> <tr> <th>sample</th> <th>batch</th> <th>replicate</th> <th>form</th> <th>diameter [cm]</th> </tr> </thead> <tbody> <tr> <td rowspan="2">T0m Sample</td> <td rowspan="2">2023-0038_SM2023_06</td> <td>1</td> <td>round</td> <td>4.5</td> </tr> <tr> <td>2</td> <td>round</td> <td>4.5</td> </tr> <tr> <td rowspan="2">T24m Sample</td> <td rowspan="2">38421_SM2020_07</td> <td>1</td> <td>round</td> <td>4.5</td> </tr> <tr> <td>2</td> <td>round</td> <td>5.0</td> </tr> </tbody> </table> <p>Clogging before and after storage of 24 months:</p> <table border="1" data-bbox="952 590 1892 853"> <thead> <tr> <th>sample</th> <th>batch</th> <th>replicate</th> <th>clogging</th> <th>Observations</th> </tr> </thead> <tbody> <tr> <td rowspan="2">T0m Sample</td> <td rowspan="2">2023-0038_SM2023_06</td> <td>1</td> <td>no</td> <td>no abnormality</td> </tr> <tr> <td>2</td> <td>no</td> <td>no abnormality</td> </tr> <tr> <td rowspan="2">T24m Sample</td> <td rowspan="2">38421_SM2020_07</td> <td>1</td> <td>no</td> <td>no abnormality</td> </tr> <tr> <td>2</td> <td>no</td> <td>no abnormality</td> </tr> </tbody> </table> <p>Delivery dose before and after storage of 24 months:</p> <table border="1" data-bbox="952 941 1892 1212"> <thead> <tr> <th>sample</th> <th>batch</th> <th>replicate</th> <th>number of strokes</th> <th>weight difference [g]</th> <th>average delivery dose [g/stroke]</th> </tr> </thead> <tbody> <tr> <td rowspan="2">T0m Sample</td> <td rowspan="2">2023-0038_SM2023_06</td> <td>1</td> <td>20</td> <td>4.27</td> <td>0.21</td> </tr> <tr> <td>2</td> <td>20</td> <td>3.28</td> <td>0.16</td> </tr> <tr> <td rowspan="2">T24m Sample</td> <td rowspan="2">38421_SM2020_07</td> <td>1</td> <td>20</td> <td>4.02</td> <td>0.20</td> </tr> <tr> <td>2</td> <td>20</td> <td>4.28</td> <td>0.21</td> </tr> </tbody> </table> <p>Particle size distribution and Mass Median Aerodynamic Diameter (MMAD)</p>	sample	batch	replicate	form	diameter [cm]	T0m Sample	2023-0038_SM2023_06	1	round	4.5	2	round	4.5	T24m Sample	38421_SM2020_07	1	round	4.5	2	round	5.0	sample	batch	replicate	clogging	Observations	T0m Sample	2023-0038_SM2023_06	1	no	no abnormality	2	no	no abnormality	T24m Sample	38421_SM2020_07	1	no	no abnormality	2	no	no abnormality	sample	batch	replicate	number of strokes	weight difference [g]	average delivery dose [g/stroke]	T0m Sample	2023-0038_SM2023_06	1	20	4.27	0.21	2	20	3.28	0.16	T24m Sample	38421_SM2020_07	1	20	4.02	0.20	2	20	4.28	0.21	<p>Andrea Fieseler, 2023 Study No: 152041205</p> <p>Marco Mullewitz, 2023 Study No: AQ23-036</p>
	sample	batch	replicate	form	diameter [cm]																																																																			
T0m Sample	2023-0038_SM2023_06	1	round	4.5																																																																				
		2	round	4.5																																																																				
T24m Sample	38421_SM2020_07	1	round	4.5																																																																				
		2	round	5.0																																																																				
sample	batch	replicate	clogging	Observations																																																																				
T0m Sample	2023-0038_SM2023_06	1	no	no abnormality																																																																				
		2	no	no abnormality																																																																				
T24m Sample	38421_SM2020_07	1	no	no abnormality																																																																				
		2	no	no abnormality																																																																				
sample	batch	replicate	number of strokes	weight difference [g]	average delivery dose [g/stroke]																																																																			
T0m Sample	2023-0038_SM2023_06	1	20	4.27	0.21																																																																			
		2	20	3.28	0.16																																																																			
T24m Sample	38421_SM2020_07	1	20	4.02	0.20																																																																			
		2	20	4.28	0.21																																																																			
	<p>MT 187: Particle size analysis by laser diffraction (Malvern</p>																																																																							

Instruments Spraytec STP5311)		To																														
		<table border="1"> <thead> <tr> <th>Sample No.</th> <th>Dv (10 %) [µm]</th> <th>Dv (50 %) [µm]</th> <th>Dv (90 %) [µm]</th> <th>% V < 10 µm [%]</th> <th>% V < 50 µm [%]</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>42.98</td> <td>145.0</td> <td>288.0</td> <td>0.73</td> <td>12.67</td> </tr> <tr> <td>2</td> <td>44.95</td> <td>120.1</td> <td>243.8</td> <td>0.82</td> <td>12.20</td> </tr> <tr> <td>3</td> <td>36.14</td> <td>115.7</td> <td>246.3</td> <td>0.99</td> <td>18.32</td> </tr> <tr> <td>Mean</td> <td>41</td> <td>127</td> <td>259</td> <td>0.8</td> <td>14.4</td> </tr> </tbody> </table>	Sample No.	Dv (10 %) [µm]	Dv (50 %) [µm]	Dv (90 %) [µm]	% V < 10 µm [%]	% V < 50 µm [%]	1	42.98	145.0	288.0	0.73	12.67	2	44.95	120.1	243.8	0.82	12.20	3	36.14	115.7	246.3	0.99	18.32	Mean	41	127	259	0.8	14.4
Sample No.	Dv (10 %) [µm]	Dv (50 %) [µm]	Dv (90 %) [µm]	% V < 10 µm [%]	% V < 50 µm [%]																											
1	42.98	145.0	288.0	0.73	12.67																											
2	44.95	120.1	243.8	0.82	12.20																											
3	36.14	115.7	246.3	0.99	18.32																											
Mean	41	127	259	0.8	14.4																											
		T24 months																														
		<table border="1"> <thead> <tr> <th>Sample No.</th> <th>Dv (10 %) [µm]</th> <th>Dv (50 %) [µm]</th> <th>Dv (90 %) [µm]</th> <th>% V < 10 µm [%]</th> <th>% V < 50 µm [%]</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>38.95</td> <td>108.9</td> <td>236.6</td> <td>0.84</td> <td>16.79</td> </tr> <tr> <td>2</td> <td>38.19</td> <td>122.3</td> <td>233.5</td> <td>1.09</td> <td>16.62</td> </tr> <tr> <td>3</td> <td>40.54</td> <td>118.2</td> <td>252.4</td> <td>0.89</td> <td>15.12</td> </tr> <tr> <td>Mean</td> <td>39</td> <td>116</td> <td>241</td> <td>0.9</td> <td>16.2</td> </tr> </tbody> </table>	Sample No.	Dv (10 %) [µm]	Dv (50 %) [µm]	Dv (90 %) [µm]	% V < 10 µm [%]	% V < 50 µm [%]	1	38.95	108.9	236.6	0.84	16.79	2	38.19	122.3	233.5	1.09	16.62	3	40.54	118.2	252.4	0.89	15.12	Mean	39	116	241	0.9	16.2
Sample No.	Dv (10 %) [µm]	Dv (50 %) [µm]	Dv (90 %) [µm]	% V < 10 µm [%]	% V < 50 µm [%]																											
1	38.95	108.9	236.6	0.84	16.79																											
2	38.19	122.3	233.5	1.09	16.62																											
3	40.54	118.2	252.4	0.89	15.12																											
Mean	39	116	241	0.9	16.2																											
		The MMAD was determined to be 127 µm before storage and 116 µm after storage.																														

Conclusion on the physical, chemical and technical properties of the product

The Insect Repellent Pump Spray IR3535® 20% is a colourless clear liquid with characteristic mild slight alcoholic odour. The pH of the undiluted ready-to-use product is between 4.4 and 5. The relative density is $D_4^{20} = 0.955$. At ambient temperature the product has a long term stability for 18 months and is stable under cold and accelerated storage conditions. Light influence is avoided by using a lightproof packaging. There are no humidity effects expected in that closed package. The product should not be stored for prolonged times at temperatures >40°C. At 20°C the surface tension is 29.581 mN/m and the viscosity 6.8 mPa.s. At 40°C the viscosity is 3.46 mPa.s. Physical and chemical compatibility with other products are not relevant.

➤ NA-MIC minor change application (2023)

A new storage stability study (24 months at ambient temperature) has been provided. The test item showed no major modification after 24 months at ambient temperature. Spraying data have also been submitted before and after storage.

The results show that the product remains stable after a storage of 24 months. The satisfactory operation of the trigger sprayer has also been demonstrated before and after storage.

Therefore, a shelf-life of 2 years can be granted for the product.

3.2.4 Physical hazards and respective characteristics

Property	Guideline and Method	Purity of the test substance (% (w/w))	Results	Reference
Explosives	Waived	-	There are no chemical groups associated with explosivity structural alerts	-
Flammable gases	Waived	-	the product is liquid	-
Flammable aerosols	Waived	-	the product is liquid	-
Oxidising gases	Waived	-	the product is liquid	-
Gases under pressure	Waived	-	the product is liquid	-
Flammable liquids	Closed cup flashpoint tester	Insect Repellent Pump Spray IR3535® 20% without Bitrex	Flash point : 28.7°C +- 2° → Classification in Flam Liq 3	Study no 242-005, Fieseler A., 2011
Flammable solids	Waived	-	the product is liquid	-
Self-reactive substances and mixtures	Waived	-	There are no chemical groups associated with self-reactive properties present in the product; apart from unsaturation, due to an aromatic 6-pieces ring which is well known to be stable, in a denaturant at very low concentration.	-
Pyrophoric liquids	Waived	-	According to the additional classification considerations in CLP Annex I, 2.9.4, the classification procedure for pyrophoric liquids need not be applied when experience in manufacture or handling shows that the liquid does not ignite spontaneously on coming into contact with air at normal temperatures (the liquid is known to be stable at room temperature for prolonged periods of time).	-
Pyrophoric solids	Waived	-	the product is liquid	-
Self-heating substances and mixtures	Waived	-	In general, the phenomenon of self-heating applies only to solids. The surface of liquids is not large enough for reaction with air and the test method is not applicable to liquids. Therefore liquids are not classified as self-heating.	-
Substances and mixtures which in contact with water emit flammable gases	Waived	-	The classification procedure for this class need not be applied if: <ul style="list-style-type: none"> ❖ the chemical structure of the substance or 	-

Property	Guideline and Method	Purity of the test substance (% (w/w))	Results	Reference
			<p>mixture does not contain metals or metalloids; or</p> <ul style="list-style-type: none"> ❖ experience in handling and use shows that the substance or mixture does not react with water, e.g. the substance is manufactured with water or washed with water; or ❖ the substance or mixture is known to be soluble in water to form a stable mixture. 	
Oxidising liquids	Waived	-	The mixture contains oxygen and this element is chemically bonded only to carbon or hydrogen.	-
Oxidising solids	Waived	-	the product is liquid	-
Organic peroxides	Waived	-	none of ingredients are classified as organic peroxides	-
Corrosive to metals	Waived	-	<p>According to the 2018 version of the TAB (note: dossier submitted in 2014) : the metal corrosivity does not to be tested if :</p> <ul style="list-style-type: none"> ❖ halogen-free ❖ no acid ❖ no base ❖ no complexing agents ❖ pH-neutral <p>The solution does not contain neither halogens, acids or base, nor complexing agents.</p> <p>The pH is not strictly neutral but is close to it .</p> <p>A full test will be requested at renewal of the dossier.</p>	-
Auto-ignition temperatures of products (liquids and gases)	EC A15 auto-ignition temperature (l & g)	Insect Repellent Pump Spray IR3535® 20% without Bitrex	Auto-ignition temperature = 440°C	Study no 242-002, Dornhagen J., 2011
Relative self-ignition temperature for solids	Waived	-	the product is liquid	-
Dust explosion hazard	Waived	-	the product is liquid	-

Conclusion on the physical hazards and respective characteristics of the product

The auto-ignition temperature of the solution is 440°C and the flashpoint of the solution is 28.7°C. The product has no self-reacting properties and does not react with air and is not self-heating since it is a liquid at room temperature. It is not able to react with metals and is not corrosive. The product is not oxidizing nor explosive but must be classified as flammable liquid, category 3 (H226).

3.2.5 Methods for detection and identification

Analytical methods for the analysis of the product as such including the active substance, impurities and residues									
Analyte (type of analyte e.g. active substance)	Analytical method	Fortification range / Number of measurements	Linearity	Specificity	Recovery rate (%)			Limit of quantification (LOQ) or other limits	Reference
					Range	Mean	RSD		
IR3535	HPLC method & UV-visible spectroscopy. The identity of IR3535 was established by comparison of the retention time and by comparison of the UV spectra obtained from sample solution and reference material.	1%/5 (1% IR3535 – 5% hydrolysis product)	Correlation of the peak area of different standard solutions with their corresponding concentrations resulted in a linear regression with regression coefficient of at least 0.999. Concentration range = from 25 to 1750 mg/L, Number of calibration points = 9	The retention time of the analyte IR3535 in the samples solution did not differ by more than 1% from the standard solution. In addition, the identity of the analyte was confirmed by comparison of the UV spectrum of the test item with the UV spectrum of	1% 94 – 110	11 0	2.3	LOD = 7 mg/L LOQ = 250 mg/L (corresponding to 5% w/w)	Study no 421-001, Meinerling M., 2007 1 st Final Report Amendment from 14 th of June 2016
		5%/5 (5% IR3535 – 5% hydrolysis product)			5% 97- 101				
		10%/10 (10% IR3535 – 1% hydrolysis product)			10% 97 – 101	10 0	5.1		
		30%/10 (30% IR3535 – 1% hydrolysis product) Validated concentration range 1 – 30% IR3535			30% 97 – 101				

				the fortified sample solution .					
<i>Hydrolysis product of IR3535: 3-(N-n-butyl-n-acetyl)aminopropionic acid</i>	HPLC method & UV-visible spectroscopy. The identity of hydrolysis product was established by comparison of the retention time and by comparison of the UV spectra obtained from sample solution and reference material.	1%/10 (10% IR3535 – 1% hydrolysis product) 1%/10 (30% IR3535 – 1% hydrolysis product) 5%/5 (1% IR3535 – 5% hydrolysis product) 5%/5 (5% IR3535 – 5% hydrolysis product) Validated concentration range 0.1 – 5% hydrolysis product. The lowest concentration comes from report 98322204 with 10% IR3535 solution (READ ACROSS from IR3535 Lotion).	Correlation of the peak area of different standard solutions with their corresponding concentrations resulted in a linear regression with regression coefficient of at least 0.999. Concentration range = from 25 to 300 mg/L, number of Calibration points = 9	The retention time of the analyte hydrolysis product in the sample solution did not differ by more than 1% from the standard solution. In addition, the identity of the analyte was confirmed by comparison of the UV spectrum of the test item with the UV-spectrum of the fortified sample solution .	1% 99 – 104 5% 99-104	10 3 99	<2.2 % <2.7 %	LOD = 3 mg/L LOQ = 50 mg/L (corresponding to 1% w/w)	Study no 421-001, Meinerling M., 2007 Statement Ibacon, 2016 Study no 98322204, Fieseler, 2015

➤ **NA-MIC minor change application (2023)**

Analytical methods for the analysis of the product as such including the active substance, impurities and residues							
Analyte (type of analyte e.g. active substance)	Analytical method	Fortification range / Number of measurements	Linearity	Specificity	Recovery rate (%)	Limit of quantification (LOQ) or other limits	Reference
IR3535	The method of analysis is based on HPLC-DAD. Specimens were quantified by measuring the response peak area of IR3535 or IR3535 free acid with reference to the calibration curve.	800 mg /L (5*5) 1200 mg/L (5*5)	Correlation coefficient (r) =1.0000 Concentration range: 500 to 1600 mg IR3535 /L n=6 y=21724*x+83752	Chromatograms of both standards, of blank formulation and a recovery sample for IR3535 (low-level spiked sample) were provided. Interferences from blank formulation were not detected and therefore not higher than 3% of the total peak area of the lowest fortification level.	Overall mean value (n=25) 98% RSD=1.6% Overall mean value (n=25) 98% RSD=2% RSDr=1.7% Hr=1.05	LOQ=800mg/L LOQ=160 g/kg	Study No. 152041228 Andrea Fieseler, 2022
IR3535 free acid	The calibration curve was obtained by correlation of peak areas of IR3535 or IR3535 free acid in the standard solutions to their corresponding concentrations.	Determination in the test item (after 24 months of storage): 2.25 mg /L (n=5)	Correlation coefficient (r) =0.9999 Concentration range: 5 to 60 mg IR3535 free acid/L n=5 y=24125*x-35149		Mean value (n=5) RSD=5.2 % RSDr=5.4% Hr=0.96	Not determined	

Conclusion on the methods for detection and identification of the product

IR3535[®] and its metabolite IR3535[®] free acid (hydrolysis product) can both be determined in the product Insect Repellent Pump Spray IR3535[®] 20% with an HPLC-Diode Array Detector/UV-VIS detector (at 220nm) and a RP18 (250*4 mm) column.

The identity of the analyte is confirmed by comparison of the retention times. The standard regression is linear. The method is repeatable. The mean recovery rates at each spiking level are in the range of 92 – 104%. Repeated injection of the samples resulted in a coefficient of variation which was less than 2.7 %. The limit of quantification (LOQ) is 5% for IR3535[®] corresponding to 250 mg/L and the limit of detection (LOD) is 7 mg/L for IR3535[®]. The limit of quantification (LOQ) is 0.1% for IR3535[®] free acid corresponding to 5 mg/L and the limit of detection (LOD) is 3 mg/L for IR3535[®] free acid. The overall mean recovery rate for IR3535[®] and IR3535[®] free acid was \geq 94%.

For other analytical methods refer to the CAR of active substance.

➤ NA-MIC minor change application (2023)

An analytical method for the determination of IR3535 in the product has been provided in the framework of the minor change application. This method is considered acceptable.

Limited data have been provided for the determination of IR3535 free acid. However, no data is required as another analytical method is available in this dossier.

3.2.6 Efficacy against target organisms

3.2.6.1 Function and field of use

Main Group 03 : Pest Control

Product Type 19 : Repellents and attractants

According to the concept label submitted by Merck (please note that Merck does not market these products):

The product ***Insect Repellent Pump Spray IR3535[®] 20%*** is presented as a ready-to-use pump spray to be applied on uncovered human skin (to face, arms, hands, legs and feet only) and on clothes.

The product is intended to be used by general public (children from 1 year old and adults) in temperate and tropical areas. An adult should apply this product to children under 10 years of age.

For an adult 3 gram product suffice.

3.2.6.2 Organisms to be controlled and products, organisms or objects to be protected

According to the use claimed by the applicant :

- The product ***Insect Repellent Pump Spray IR3535[®] 20%*** is intended to be used to repel arthropods on skin and clothes.
- The target organisms to be controlled are mainly mosquitoes and ticks. This product is also intended to repel biting flies (stable flies, black flies, sand flies), deer flies, biting midges, house flies, wasps and bees from treated skin and clothing preventing respective consequences.

- The organisms to be protected are humans.

3.2.6.3 Effects on target organisms, including unacceptable suffering

The applicant submitted 4 studies. Please see the summary (and comments) of all the studies submitted in the table section 2.2.6.5.

3.2.6.4 Mode of action, including time delay

The mode of action of IR3535® is not a passive masking of an attracting odour of a victim, but an active repellent effect as insects avoid entering regions with IR3535® vapours. The exact biochemical mode of action of IR3535® on insects is not well known yet, but it is most self-evident to assume that IR3535® has an olfactory-based effect.

3.2.6.5 Efficacy data

Experimental data on the efficacy of the biocidal product against target organism(s)							
Function	Field of use envisaged	Test substance	Test organism(s)	Test method	Test system / concentrations applied / exposure time	Test results: effects	Reference
PT19 Repellent	<ul style="list-style-type: none"> - RTU pump spray - Applied on uncovered human skin - For consumers - In temperate and tropical areas 	<p>US Pump Spray Formulation</p> <p>Hydroalcoholic solution</p>	<p>TICKS <i>Ixodes scapularis</i> (US deer ticks) nymphs</p> <p>Given the information provided by DE eCA (Büchel et al. - 2015 - "Repellent efficacy of DEET, Icaridin, and EBAAP against <i>Ixodes ricinus</i> and <i>Ixodes scapularis</i> nymphs (Acari, Ixodidae).") during the commenting phase, no significant differences in repellent efficacy were found between the two species tested (when compared the repellent efficacy of 10% EBAAP =IR3535)."</p>	Lab test	<ul style="list-style-type: none"> - with 10 volunteers - 0.00067 g BP/cm² on the lower arm - Exposure started 15 minutes after application - 3 min exposure time, every 15 min until 14 hours - "normal" climatic conditions for temperate areas (+19-26°C ; 31-52% rH) 	<p>12 hours complete protection</p> <p>In temperate areas only</p>	<p>Doc N° 336-1918/2006</p> <p>Reliability 1 Key study</p>
1PT19 Repellent	<ul style="list-style-type: none"> - RTU spray - Applied on uncovered human skin - For consumers - In temperate and tropical areas 	<p>US Pump Spray Formulation</p> <p>Hydroalcoholic solution</p>	<p>MOSQUITOES <i>Aedes melanimon</i> (predominant species), <i>Culex erythrothorax</i>, <i>Culex tarsalis</i>, <i>Culiseta incidens</i>, <i>Anopheles freeborni</i> and <i>Aedes vexans</i></p> <p>With very high mosquito pressure</p>	Field test on 2 different sites (Forest and Marsh/Pasture)	<ul style="list-style-type: none"> - with 20 volunteers - 0.00067 g/cm² for arms (and 0.00051 g/cm² for legs). - Exposure started 2h (Forest) or 3h (Marsh/Pasture) after application - 1 min exposure time, every 15 min until 14 hours - "normal" climatic conditions for temperate areas (+19-25°C ; 24-39% rH) 	<p>8 hours complete protection</p> <p>In temperate areas only</p>	<p>Doc N° 336-1919/2006</p> <p>Reliability 1 Key study</p>
PT19 Repellent	<ul style="list-style-type: none"> - RTU spray - Applied on uncovered human skin - For consumers 	<p>Insect Repellent Pump spray (15% IR3535)</p>	<p>TICKS <i>Ixodes ricinus</i> (EU sheep ticks) nymphs</p>	Lab test	<ul style="list-style-type: none"> - with 11 volunteers - 1 g BP/600 cm² on the forearm - Exposure started immediately after application - 5 min exposure time, every 15 min 	<p>8 hours complete protection</p> <p>In temperate areas only</p>	<p>Doc N° 336-1921/2006</p> <p>Supportive study</p>

	- In temperate and tropical areas				- "normal" climatic conditions for temperate areas (+23.2-25.4°C ; 24.2±3.7% rH)	e areas only	
PT19 Repellent	- RTU spray - Applied on uncovered human skin - For consumers - In temperate and tropical areas	The composition of the product tested is not reported TMT-003	MOSQUITOES <i>Aedes albopictus</i>	"Arm-in-cage" simulated-use test	ND	ND	Doc N° 336-1922/2006 Reliability 4

Conclusion on the efficacy of the product

The product **Insect Repellent Pump Spray IR3535® 20%** (hydroalcoholic solution, 20% IR3535) when used at a dose of 0.00067 g/cm² provides up to 12 hours complete protection time against ticks found in temperate areas.

The product **Insect Repellent Pump Spray IR3535® 20%** (hydroalcoholic solution, 20% IR3535) when used at a dose of 0.00067 g/cm² for arms (and 0.00051 g/cm² for legs) provides up to 8 hours complete protection time against mosquitoes found in temperate areas.

3.2.6.6 Occurrence of resistance and resistance management

There are no reported cases of resistance developing in the literature so far.

3.2.6.7 Known limitations

- As stated by the applicant, the product is intended to be used in tropical areas. But, due to the absence of efficacy tests on tropical species (at more than +30°C), the use of this product in tropical areas hasn't been authorized.
- As stated by the applicant, the product is intended to be used on skin against black flies, horse-flies, wasps and bees. But, due to the absence of relevant efficacy tests, these uses of the product haven't been authorized.
- As stated by the applicant, the product is intended to be used on clothes. But, due to the absence of efficacy tests and good results on clothes, this use of the product hasn't been authorized.

3.2.6.8 Evaluation of the label claims

According to the label, the product ***Insect Repellent Pump Spray IR3535®*** (hydroalcoholic solution, 20% IR3535) does provide a good protection against ticks and mosquitoes during 8 hours in temperate and tropical areas.

Based on the efficacy tests submitted and validated, this claim is partially supported i.e. only for a use in temperate areas.

For products claiming protection against mosquitoes & ticks such as the product ***Insect Repellent Pump Spray IR3535®*** (hydroalcoholic solution, 20% IR3535), the protection time against mosquitoes & ticks found in temperate areas would be of 8h when used at 0.00067 g/cm², based on the efficacy tests submitted and validated.

For products claiming protection against mosquitoes only, the protection time against mosquitoes found in temperate areas would be of 8h when used at 0.00067 g/cm² for arms (and 0.00051 g/cm² for legs), based on the efficacy tests submitted and validated.

For products claiming protection against ticks only, the protection time against ticks found in temperate areas would be of 12h when used at 0.00067 g/cm², based on the efficacy tests submitted and validated.

Remark : Mentioning on the label application rate (such as 0.00167 g product/cm²) is not easy to observe and useless for the consumer. Therefore, the efficacy expert is of the opinion to put on the label more friendly consumer use instructions such as "Apply sparingly to uniformly cover uncovered parts of the body (face, hands, arms, legs and feet only)".

- References related to intended uses under tropical conditions must be removed from the label
- References related to intended uses on clothes must be removed from the label
- All references related to target organisms other than ticks and mosquitoes must be removed from the label.

- All the warnings such as "Applying sun care products or cosmetic formulations after repellent use will decrease the efficacy of the repellent considerably", "Do not apply over cuts, wounds, freshly shaven or irritated skin" and "Mechanical protection (clothing, mosquito nets) is to be preferred" must be mentioned on the label.

3.2.6.9 Relevant information if the product is intended to be authorised for use with other biocidal product(s)

N.D.

3.2.7 Risk assessment for human health

3.2.7.1 Assessment of effects on Human Health

Acute dermal toxicity, skin and eye irritation and sensitising properties were assessed using formula EUS26-15 Insect Repellent Spray (US Pump Spray Formulation). The test substance can be regarded as representative for the product under evaluation. The main difference between the 2 formulas is the presence (EUS26-15) / absence (product under evaluation) of a small amount of denaturant. The harmonized classification of the substance in question indicates that it will not affect the results of the properties tested. For details, see section 2.2.2 and confidential part of the PAR.

(I) Skin corrosion and irritation

New data for this section are due to differences in product composition.

Summary table of animal studies on skin corrosion /irritation					
Method, Guideline, GLP status, Reliability	Species, Strain, Sex, No/group	Test substance, Vehicle, Dose levels, Duration of exposure	Results <i>Average score (24, 48, 72h)/ observations and time point of onset, reversibility; other adverse local / systemic effects, histopathological findings</i>	Remarks (e.g. major deviations)	Reference
OPPTS 870.2500 OECD 404 EU 92/69 Annex V, B4 GLP=yes Rel=1	Albino rabbit New Zealand White 2♂, 1♀ 1 test group, 3 animals	EUS26-15 Insect Repellent Spray No vehicle 0.5 ml / 2.5 cm x 2.5 cm 4h	Erythema: 24h: 1.0 48h: 0.6 72h: 1.0 Edema: 24h: 1.0 48h: 0.6 72h: 0.3 Very slight erythema and edema. Max score erythema 1, earliest onset 0.5-1h; max score edema 1, earliest onset 0.5-1h. Very slight erythema persisted for 2 animals through study termination. No deaths, no remarkable bw changes	US Pump Spray Formulation	██████████ 2006 (a)

Individual and mean dermal scores for erythema and edema (, 2006 (a))																
Animal	Sex	Site	Erythema							Edema						
			0.5 - 1 h	24 h	48 h	72 h	4 d	7 d	14 d	0.5 - 1 h	24 h	48 h	72 h	4 d	7 d	14 d
45169	M	B	1	1	1	1	1	1	1	1	1	1	0	0	0	0
45171	M	D	1	1	0	1	1	1	0	0	1	0	0	0	0	0
45186	F	B	1	1	1	1	1	1	1	0	1	1	1	1	1	0
Means 24-72 hours (individual animals)																
45169	1							0.67								
45171	0.67							0.33								
45186	1							1								
Mean 24-72 hours (all animals)																
0.89							0.67									

There were no deaths or remarkable body weight changes noted during the study. Dermal findings for the 4-hour exposure sites consisted of very slight erythema and edema (grade 1). Very slight erythema persisted for two animals through study termination. Based on the evaluation according to EU criteria, the mean scores at 24-72 hours for erythema and edema were calculated to be 0.89 and 0.67, respectively.

The mean scores determined for erythema (0.89) and edema (0.67) do not require a classification according to the EU and GHS classification and labelling system.

Although erythema grade 1 (very slight erythema, barely perceptible, area of edges not well defined) persisted in two out of three animals until the end of the 14-day post-observation period, a classification as a potential skin irritant is not required. According to EU Directive 2001/59/EC or Regulation (EC) No. 1272/2008 (CLP), a classification as a skin irritant should be considered when hyperplasia, hyperkeratosis, scaling, discoloration, fissures, scabs or alopecia persist in two or more animals at the end of the observation period which has not been observed in the skin irritation study with Insect Repellent Pump Spray IR3535® 20 %.

No *in vitro* or human data are available for skin corrosion/irritation.

Conclusion used in Risk Assessment – Skin corrosion and irritation	
Value/conclusion	Biocidal product not classified for skin corrosion/irritation according to (EU) nr. 1272/2008
Justification for the value/conclusion	Mean scores for erythema and edema do not trigger a classification. Severity of skin reactions that persisted to the end of the observation period was limited (erythema grade 1).

Classification of the product according to CLP and DSD	none
--	------

(II) Eye Irritation

New data for this section are due to differences in product composition.

Summary table of animal studies on serious eye damage and eye irritation					
Method, Guideline, GLP status, Reliability	Species, Strain, Sex, No/group	Test substance, Dose levels, Duration of exposure	Results Average score (24, 48, 72h)/ observations and time point of onset, reversibility	Remarks (e.g. major deviations)	Reference
OPPTS 870.2400 OECD 405 EU 92/69 Annex V, B5 GLP=yes Rel=1	Albino rabbit New Zealand White 2♂, 1♀ 1 test group, 3 animals	EUS26-15 Insect Repellent Spray No vehicle 0.1ml 1 single unwashed exposure	Cornea: 24h: 2.0 48h: 1.3 72h: 1.0 Iris: 24h: 0.0 48h: 0.0 72h: 0.0 Conjunctiva; redness: 24h: 3.0 48h: 3.0 72h: 2.3 Conjunctiva; chemosis: 24h: 2.3 48h: 2.3 72h: 2.0 Reversibility: Yes Earliest onset for all symptoms: 1h Max scores: cornea 2, conjunctiva, redness 3, conjunctiva, chemosis 4 Reversible at d14 2 out of 3 animals: average corneal opacity ≥ 1 , average conjunctival redness ≥ 2	US Pump Spray Formulation	██████████ (2006) (b)

Individual Total Scores and for Ocular Irritation (, 2006 (b))												
Rabbit No/sex Time after treatment [hours]	No. 45158/male				No. 45170/male				No. 45182/female			
	1	24	48	72	1	24	48	72	1	24	48	72
Cornea												
Opacity	1	2	1	0	2	2	2	2	1	2	1	1
Area involved	1	2	2	0	1	4	4	3	1	2	1	1
Iris	0	0	0	0	0	0	0	0	0	0	0	0
Conjunctivae												
Redness	3	3	3	2	3	3	3	3	3	3	3	2
Chemosis	4	2	3	3	3	2	2	1	4	3	2	2
Discharge	3	2	2	0	3	3	2	1	3	2	2	1
Mean of 24-72-hour Readings: individual animals	Opacity: 1 Iris: 0 Redness: 2.7 Chemosis: 2.7				Opacity: 2 Iris: 0 Redness: 3 Chemosis: 1.7				Opacity: 1.33 Iris: 0 Redness: 2.7 Chemosis: 2.3			
Mean of 24-72-hour Readings: all animals	Opacity: 1.44 Iris: 0 Redness: 2.8 Chemosis: 2.2											
Classification	Irritant (EU: Xi, R36; GHS: Eye Irrit. 2, H319)											

There were no deaths or remarkable body weight changes noted during the study. Positive corneal and conjunctival irritations were noted for all animals. Corneal irritation subsided by study day 10 and conjunctival irritation subsided by study day 14. The left (control) eyes were free of evidence of ocular irritation and other findings for the duration of the study. According to EU and CLP criteria, the mean scores for corneal reactions, iritis, conjunctival redness and chemosis were 1.44, 0, 2.8 and 2.2, respectively, resulting in a classification as a potential eye irritant (EU criteria: Xi, R36; GHS criteria: Eye Irrit. 2, H319).

Based on the results obtained in the eye irritation study with EUS26-15 Insect Repellent Spray in rabbits, the biocidal product is a potential eye irritant and needs to be classified with respect to eye irritancy (EU criteria: Xi, R36; GHS criteria: Eye Irrit. 2, H319).

No *in vitro* or human data are available for eye corrosion/irritation.

Conclusion used in Risk Assessment – Eye irritation	
Value/conclusion	the biocidal product has to be classified as a potential eye irritant according to (EU) nr. 1272/2008 (Eye Irrit. 2, H319)
Justification for the value/conclusion	average score was ≥ 1 for corneal opacity and ≥ 2 for conjunctival redness and chemosis in 2 out of 3 animals
Classification of the product according to CLP and DSD	Eye damage/irritation cat 2, H319

(III) Respiratory tract irritation

Conclusion used in the Risk Assessment – Respiratory tract irritation	
Justification for the conclusion	Neither the active ingredient nor one of the other relevant ingredients of the biocidal product are classified with respect to respiratory tract irritation. Insect Repellent Pump Spray IR3535® 20 % does not pose a respiratory tract irritation hazard.
Classification of the product according to CLP and DSD	There is no indication that a classification with respect to respiratory tract irritation is necessary for Insect Repellent Pump Spray IR3535® 20 %.

(IV) Skin sensitization

Summary table of animal studies on skin sensitisation					
Method, Guideline, GLP status, Reliability	Species, Strain, Sex, No/group	Test substance, Vehicle, Dose levels, duration of exposure Route of exposure (topical/intradermal, if relevant)	Results (EC3-value or amount of sensitised animals at induction dose); evidence for local or systemic toxicity (time course of onset)	Remarks (e.g. major deviations)	Reference
OECD 406 OPPTS 870.2600 EU 92/69 Annex V, B6 GLP=yes Rel=1	Guinea pig Hartley [CrI: HA] 10 ♂ and 10 ♀/ test group 5 ♂ and 5 ♀/ naive control group	EUS26-15 Insect Repellent Spray No vehicle Undiluted 0.3 ml/site 6h exposure Epicutaneous, occlusive	No positive dermal reactions in the test or the naive control groups No deaths, no test article related clinical findings, no remarkable bw changes	US Pump Spray Formulation	(2006) (c)

Dermal Observations and Severity Indices (, 2006 (c))														
Dermal Scores														
Group	Material	24 hour					48 hour					Severity Index		Incidence Index
		0	+/-	1	2	3	0	+/-	1	2	3	24 h	48 h	
Test		17	3	0	0	0	16	4	0	0	0	0.1	0.1	0 %
Naive Control-I		10	0	0	0	0	9	1	0	0	0	0.0	0.1	NA

TA = Test Article
NA = Not Applicable

The skin sensitisation potential of EUS26-15 Insect Repellent Spray was evaluated using the modified Buehler test method.

Animal welfare benefits and scientific advantages make the LLNA the preferred test for sensitization. However, existing data of good quality derived from a Buehler test should be acceptable as they preclude the need for further in vivo testing. As none of the cosmetic ingredients in

the formulation have a sensitizing potential and as the active substance is not considered as sensitizing (Buehler test and Photoallergenicity maximisation test), the Buehler test was regarded as acceptable.

There were no deaths, nor were there any test article-related clinical findings or remarkable body weight changes during the study period. Following challenge dosing with EUS26-15 Insect Repellent Spray, there were no positive dermal reactions (score ≥ 1) in the test or the naive control groups. The Incidence Index for the test group with a score ≥ 1 was 0 % (0/20) following challenge dosing.

In the positive control experiments which were performed as a separate study, the positive control substance HCA was a sensitizer when administered as both a 10 % concentration in 70/30 (v/v) in acetone/PEG 400 and a 20 % concentration in 70/30 (v/v) in acetone/PEG 400 under the conditions of the study. The mean incidence indices for the positive controls were 20 % and 60 % at a concentration of 10 % and 20 %, respectively. This confirms the reliability of the test system as indicated by the dose-response relationship.

EUS26-15 Insect Repellent induced no skin sensitisation reactions in albino guinea pigs when using the modified Buehler test method. A classification with respect to skin sensitisation is not required.

No *in vitro* or human data are available for skin sensitisation.

Conclusion used in Risk Assessment – Skin sensitisation	
Value/conclusion	Biocidal product not classified for skin sensitisation according to (EU) nr. 1272/2008
Justification for the value/conclusion	Following challenge dosing with EUS26-15 Insect Repellent Spray, there were no positive dermal reactions (score ≥ 1) in the test or the naive control groups. The Incidence Index for the test group with a score ≥ 1 was 0 % (0/20) following challenge dosing.
Classification of the product according to CLP and DSD	none

(V) Respiratory sensitization (ADS)

Conclusion used in Risk Assessment – Respiratory sensitisation	
Value/conclusion	
Justification for the value/conclusion	None of the ingredients of the product is known to be sensitizing to the respiratory tract. Moreover, from tests in guinea pigs the product was proven not to exert any skin sensitizing properties. In addition, the active ingredient IR3535® did not show a sensitizing or photosensitizing potential from tests in guinea pigs.

	Finally, IR3535® products are on the market for more than 40 years and there are no indications for any sensitizing potential neither to the skin nor to the respiratory tract. Based on all this data it is thus concluded that the product is not sensitizing to the respiratory tract.
Classification of the product according to CLP and DSD	none

(VI) Acute toxicity*a. Acute toxicity by oral route*

Value used in the Risk Assessment – Acute oral toxicity	
Value	Biocidal product not classified for acute oral toxicity according to (EU) nr. 1272/2008
Justification for the selected value	Neither the active ingredient nor one of the other relevant ingredients of the biocidal product are classified with respect to acute oral toxicity. Thus, Insect Repellent Pump Spray IR3535® 20 % has no potential for an acute oral toxicity hazard and no classification with respect to acute oral toxicity is required. No human data are available for acute oral toxicity.
Classification of the product according to CLP and DSD	none

Data waiving	
Information requirement	Acute oral toxicity: Study scientifically unjustified
Justification	Since the acute oral toxicity of Insect Repellent Pump Spray IR3535® 20 % can be assessed on the basis of the properties of the ingredients, the performance of an acute oral toxicity study with the biocidal product is scientifically not justified. See IUCLID data point 8.5.1 Endpoint study record: Acute toxicity: oral.001. There are valid data available on each of the components in the mixture sufficient to allow classification of the mixture according to the rules laid down in Regulation (EC) No 1272/2008 (CLP), and synergistic effects between any of the components are not expected.

b. Acute toxicity by inhalation

No human data are available for acute inhalation toxicity.

Value used in the Risk Assessment – Acute inhalation toxicity	
Value	Biocidal product not classified for acute toxicity (inhalation) according to (EU) nr. 1272/2008
Justification for the selected value	None of the components of the biocide are classified for acute inhalation toxicity according to (EU) nr. 1272/2008.
Classification of the product according to CLP and DSD	none

Data waiving	
Information requirement	Acute inhalation toxicity: Study scientifically unjustified
Justification	<p>Since the acute inhalation toxicity of Insect Repellent Pump Spray IR3535® 20 % can be assessed on the basis of the properties of the ingredients, the performance of an acute inhalation toxicity study with the biocidal product is scientifically not justified. See IUCLID data point 8.5.2 Endpoint study record: Acute toxicity: inhalation.001.</p> <p>There are valid data available on each of the components in the mixture sufficient to allow classification of the mixture according to the rules laid down in Regulation (EC) No 1272/2008 (CLP), and synergistic effects between any of the components are not expected.</p>

c. *Acute toxicity by dermal route*

Summary table of animal studies on acute dermal toxicity						
Method, Guideline, GLP status, Reliability	Species, strain, Sex, No/group	Test substance, Vehicle, Dose levels, Surface area	Signs of toxicity (nature, onset, duration, severity, reversibility)	LD50	Remarks (e.g. major deviations)	Reference
OECD 402 EU 92/69 Annex V, B.3 EPA OPPTS 870.1200 GLP=yes Rel=1	Rat CrI:CD(SD) 5♀, 5♂/dose	EUS26-15 Undiluted 5000 mg/kg bw 10% of body area Semiocclusive	See below	>5000 mg/kg bw	US Pump Spray Formulation	██████████ (2006) (d)

There were no deaths, remarkable body weight changes or macroscopic findings at the scheduled necropsy. Clinical findings noted persisted until day 1 post-dosing and included abnormal excretion, and various discoloured areas due to discharges/excretions which were observed. Dermal findings noted during the study consisted of very slight erythema (grade 1) and pinpoint scabbing at the dose sites. Very slight erythema (grade 1) persisted until study termination on day 14.

Based on the results of this study, the LD₅₀ of EUS26-15 Insect Repellent Spray was greater than 5000 mg/kg bw when administered once for 24 hours to the clipped, unabraded skin of male and female albino rats. A classification of the biocidal product with respect to acute dermal toxicity is not required.

No human data are available for acute dermal toxicity.

Value used in the Risk Assessment – Acute dermal toxicity	
Value	Biocidal product not classified for acute dermal toxicity according to (EU) nr. 1272/2008
Justification for the selected value	In an acute dermal toxicity study, the LD ₅₀ of EUS26-15 Insect Repellent Spray was greater than 5000 mg/kg bw.
Classification of the product according to CLP and DSD	none

(VII) Information on dermal absorption

In a dermal toxicokinetics/metabolism study with 5 male and 5 female human volunteers, the dermal absorption of the active substance IR3535® from a pump spray containing 20% IR3535® has been determined in parallel (██████, 2010). In this study, approx. 3 grams of the formulation were applied once to hands, arms, legs, feet, face and neck of each volunteer (ca. 64% of total body area). The total amount of IR3535® and its metabolite IR3535®-free acid excreted with the urine over a period of 48 hours presented 13.3% of the dermal dose of IR3535® applied. Since IR3535® is rapidly and extensively metabolized and as IR3535®-free acid has a low molecular weight and high water solubility, it is expected that urinary excretion of IR3535®-free acid and IR3535® represents the total extent of absorption of IR3535® in humans and a distribution to organs and tissues is considered to be negligible. The results of this study have been summarized in the active substance dossier and were assessed for the approval of IR3535®.

The assessment of this study resulted in an overall dermal penetration of 14% IR3535®.

Since the composition of Insect Repellent Pump Spray IR3535® 20 % and the concentration of IR3535® is identical to the product tested in the dermal toxicokinetics/metabolism study, a separate skin absorption study with the biocidal product can be waived. Instead, the skin absorption of 14% for IR3535® can be applied to Insect Repellent Pump Spray IR3535® 20%. A dermal penetration of 14% will be used in the human exposure assessments for the intended use of the biocidal product.

See IUCLID datapoint 8.6 Dermal absorption Endpoint study record: Dermal absorption.001.

Value(s) used in the Risk Assessment – Dermal absorption		
Substance	Insect Repellent Pump Spray IR3535® 20%	
Value(s)*	14% dermal absorption for 20% IR3535 lotion/ cream formulations	
Justification for the selected value(s)	human volunteer study on a water/ethanol-based 20 % IR3535® formulation (██████, 2010)	

Data waiving	
Information requirement	Skin absorption study
Justification	Human volunteer study on a water/ethanol-based 20 % IR3535® formulation

(VIII) Available toxicological data relating to non active substance(s) (i.e. substance(s) of concern)

There are valid data available on each of the components in the mixture sufficient to allow classification of the mixture according to the rules laid down in Directive 1999/45/EC and Regulation (EC) No 1272/2008 (CLP), and synergistic effects between any of the components are not expected.

(IX) Available toxicological data relating to a mixture

Available toxicological data relating to a mixture that a substance(s) of concern is a component of

There are valid data available on each of the components in the mixture sufficient to allow classification of the mixture according to the rules laid down in Directive 1999/45/EC and Regulation (EC) No 1272/2008 (CLP), and synergistic effects between any of the components are not expected.

(X) Other

Not applicable.

3.2.7.2 Exposure assessment

The active substance contained in the product Insect Repellent Pump Spray IR3535® 20 % is the same as evaluated in the CAR for IR3535® and therefore no new data/information on the active substance is required.

The composition of the representative product from the CAR is not identical to that of Insect Repellent Pump Spray IR3535® 20 %. However, the intended use is identical as well as the amount of active substance in both products. It does not contain substances of toxicological concern apart IR3535®.

Following the referral conclusions for this product, it has been decided that Ethanol should be considered as a substance of concern, since it is responsible for the classification of the biocidal product as a flammable liquid.

However, from a toxicological point of view, ethanol is not considered relevant. Based on its harmonized classification, ethanol is not classified for any human health hazard. Considering the fact that there is currently no guidance of how to treat physico-chemical hazard, it was agreed that the application of P-sentences and H-sentences will cover the risk, based on an analogy with the Human Health document CA-Nov14-Doc 5.11 when substances are classified in band A.

Consequently, no risk assessment was performed for ethanol. Identification of main paths of human exposure towards active substance(s) and substances of concern from its use in biocidal product

Summary table: relevant paths of human exposure							
Exposure path	Primary (direct) exposure			Secondary (indirect) exposure			
	Industrial use	Professional use	Non-professional use	Industrial use	Professional use	General public	Via food
Inhalation	n.a.	n.a.	Yes	n.a.	n.a.	Yes	n.a.
Dermal	yes	n.a.	Yes	n.a.	n.a.	Yes	n.a.
Oral	n.a.	n.a.	n.a.	n.a.	n.a.	Yes	n.a.

For primary exposure, the most relevant route of exposure is the dermal route. During the application phase, inhalation exposure is possible resulting from respiring aerosols after spraying. It was considered that the respirable particles will be absorbed via the lower airways and that the non-respirable particles will precipitate in the upper airways and be taken in orally. Direct oral exposure is not considered to be relevant because of the repellent taste (bad palatability) of the active substance and because the biocidal product is not intended to be applied by children younger than 11 years.

For secondary exposure, dermal exposure is possible for adults treating or handling children. However this scenario is fully covered by primary adult dermal exposure. Hand to mouth transfer is also possible for adults and children; nonetheless, the biocidal product is not intended to be applied on children's hands which reduces potential oral uptake of the dermally applied active substance. For inhalative exposure, the inhalation of volatilized residues after application is also relevant.

(I) General informationGeneral default values for exposure assessment

Default value considering age groups ¹			
Age groups	Body weight [kg]	Respiration rate [m ³ /air/hour]	Total body surface area [cm ²]
ADULT irrespective of gender (based on female 30 to <40 years old)	60	1.25	16600
CHILD 6 to < 12 years old irrespective of gender (based on female 6 to <11 years old)	23.9	1.32	9200
CHILD 2 to < 6 years old irrespective of gender (based on data from female 2 to <6 years old)	15.6	1.26	6800
TODDLER 1 to <2 years old irrespective of gender (based on female 1 to <2 years old)	10	1.26	4800
INFANT < 1 year old irrespective of gender (based on female 6 to <12 months old)	8	0.84	4100

¹ Recommendation no. 14 of the BPC Ad hoc Working Group on Human Exposure Default human factor values for use in exposure assessments for biocidal products (revision of HEEG opinion 17 agreed at the Human Health Working Group III on 12 June 2017)

Treated surface, applied amount of biocidal product and number of application per day:**Treated surface:**

The treated surface is assumed to be the uncovered parts of the body. According Recommendation no. 11 of the BPC Ad hoc Working Group on Human Exposure : Proposal for harmonising the assessment of human exposure to repellents (PT19) (Version 2.1 agreed at Human Health Working Group V on 22 November 2017), the uncovered body surface area corresponds to 55% of the total body surface.

Amount of biocidal product:

Following the efficacy assessment for this product, the efficacious application rate is : 0.00067 g product/cm² skin against ticks and 0.00067 g/cm² for legs (and 0.00051 g/cm² for arms) against mosquitoes.

Therefore, the application rate is considered to be **0.67 mg/cm²**.

Number of application per day:

The applicant proposes that : *"Insect Repellent Pump Spray IR3535® 20% is intended to be used in summer when insects are frequent. It is usually applied once a day depending on outdoor activities, weather and presence of insects. The application can be repeated when necessary (noticeable reduction in repellence). The pump spray can be applied up to 3 times per day for adults, up to 2 times for children between the age of 3 and 10 years and maximally 1 time per day for children below 3 years."*

Summary : Amount of product used per application for the different age groups, treated surface and number of application per day			
Age groups	Amount of product used per application [g]	Treated surface [cm²]	number of applications per day
ADULT irrespective of gender (based on female 30 to <40 years old)	6.1171	9130	3 applications/day
CHILD 6 to < 12 years old irrespective of gender (based on female 6 to <11 years old)	3.3902	5060	2 applications/day
CHILD 2 to < 6 years old irrespective of gender (based on data from female 2 to <6 years old)	2.5058	3740	2 applications/day
TODDLER 1 to <2 years old irrespective of gender (based on female 1 to <2 years old)	1.7688	2640	1 application/day
INFANT < 1 year old irrespective of gender (based on female 6 to <12 months old)	1.51085	2255	1 application/day

Dermal, inhalatory and oral absorption:

- Inhalatory absorption : 100 %
- Dermal absorption : 14 %
- Oral absorption : 100 %

(II) List of scenarios

Insect Repellent Pump Spray IR3535® 20 % is used by the general public. The primary route of exposure is dermal.

Oral exposure by hand-to-mouth transfer is not considered to be a significant route of primary exposure, because of the repellent taste (bad palatability) of the active substance, thus, preventing repeated mouthing of IR3535® by children and infants. Furthermore, the biocidal product is not intended to be applied by children younger than 11 years which makes an oral uptake of the dermally applied active substance inconsiderable.

A potential inhalation exposure is only possible during the application phase via spraying. After application, no inhalation exposure risk is anticipated due to the low vapour pressure of IR3535®. Moreover, it has to be taken into account that the exposure time to the spray is extremely short and that it is not recommended to spray the biocidal product directly onto the face.

Dermal secondary exposure is possible for adults treating or handling children. However, this scenario is fully covered by primary adult dermal exposure. A parent applying (spraying) the product on children and herself/himself has been taken into account for inhalative secondary exposure.

Hand to mouth transfer has been developed consistently with the DEET dossier. It was proposed to use a reverse scenario to estimate this exposure.

Inhalation of volatilized residues after application is relevant based on the HEEG opinion on Assessment of Inhalation Exposure of Volatilized Biocide Active Substance. The exposure to volatilised residues indoors was calculated using ConsExpo model..

Summary table: scenarios			
Scenario number	Scenario (e.g. mixing/loading)	Primary or secondary exposure Description of scenario	Exposed group (e.g. professionals, non-professionals, bystanders)
1.	Application phase	Primary exposure: Dermal exposure assessment for adults, children, toddlers and infants.	Non-professionals
2.	Application phase	Primary exposure: Inhalation exposure assessment for adults, children, toddlers and infants.	Non-professionals
3.	Post-application phase	Secondary exposure (indirect exposure as a result of use): Hand-mouth transfer reverse reference scenario (oral exposure)	Non-professionals
4.	Post-application phase	Parent treating two children and himself/herself (spraying) (combined inhalative and oral exposure)	Non-professionals
5.	Post-application phase	Inhalation of volatilised residues after application (inhalative exposure)	Non-professionals
6.	Exposure during production	Mixing and Loading model – worst case for the production, formulation and disposal of the biocidal product	Professionals

(III) Industrial exposure

There is no concern about industrial exposure because of the intend of use apart for the production/formulation and disposal of the biocidal product. This exposure is addressed under a point below (scenario 6).

(IV) Professional exposure

Not relevant since the product Insect Repellent Pump Spray IR3535® 20 % is intended to be used by general public.

(V) Non-professional exposure

Scenario 1: Primary exposure: Dermal exposure assessment for adults, children, toddlers and infants.

Description of Scenario 1		
This scenario is based on the one available in the CAR of IR3535 [®] . It has been updated with the document : Biocide Human Health Exposure Methodology (Oct 2015).		
Dermal exposure: Number of application/day x amount b.p./application x percent of a.s. in b.p.		
Systemic exposure: Dermal exposure x percent of dermal absorption		
Dermal systemic exposure: Systemic exposure / body weight		
	Parameters	Value
For All categories	Dermal absorption ¹	14%
	% of active substance in biocidal product ¹	20%
Tier 1- Adult	Number of application / day ¹	3
	Body weight ¹	60 kg
	Amount of biocidal product/ application ¹	6.12 g
Tier 1- Child 6 to < 12 years old	Number of application / day ¹	2
	Body weight ¹	23.9 kg
	Amount of biocidal product/ application ¹	3.39 g
Tier 1- Child 2 to < 6 years old	Number of application / day ¹	2
	Body weight ¹	15.6 kg
	Amount of biocidal product/ application ¹	2.51 g
Tier 1- Toddler	Number of application / day ¹	1
	Body weight ¹	10 kg
	Amount of biocidal product/ application ¹	1.77 g
Tier 1- Infant	Number of application / day ¹	1
	Body weight ¹	8 kg
	Amount of biocidal product/ application ¹	1.51 g
Tier 2- Adult	Number of application / day ²	2
Tier 2- Child 6 to < 12 years old	Number of application / day ²	1
Tier 2- Child 2 to < 6 years old	Number of application / day ²	1
Tier 3- Adult	Number of application / day ²	1

¹ General information, see justification above

² Limitation of the exposure

Calculations for scenario 1

Summary table: estimated exposure for Dermal Primary exposure		
Exposure scenario	Tier/PPE	Estimated dermal uptake
Scenario 1 – ADULT 3 applications/day	Tier 1 / no PPE	8.56 mg/kg bw/day
Scenario 1 – CHILD (6-12) 2 applications/day	Tier 1 / no PPE	7.94 mg/kg bw/day
Scenario 1 – CHILD (2-6) 2 applications/day	Tier 1 / no PPE	8.99 mg/kg bw/day
Scenario 1 – TODDLER 1 application/day	Tier 1 / no PPE	4.95 mg/kg bw/day
Scenario 1 – INFANT 1 application/day	Tier 1 / no PPE	5.29 mg/kg bw/day
Scenario 1 – ADULT 2 applications/day	Tier 2 / no PPE	5.71 mg/kg bw/day
Scenario 1 – CHILD (6-12) 1 application/day	Tier 2 / no PPE	3.97 mg/kg bw/day
Scenario 1 – CHILD (2-6) 1 application/day	Tier 2 / no PPE	4.50 mg/kg bw/day
Scenario 1 – ADULT 1 application/day	Tier 3 / no PPE	2.85 mg/kg bw/day

Scenario 2: Primary exposure: Inhalation exposure assessment for adults, children, toddlers and infants.

Description of Scenario 2

This scenario is based on the one available in the CAR of IR3535®. It has been adapted with the documents : Biocide Human Health Exposure Methodology (Oct 2015) and Guidance on the biocidal products Regulation (volume III Human Health – Part B Risk Assessment, Oct 2015).

Model used: "Consumer spraying and dusting model 2 - Hand-held trigger spray" from Biocide Human Health Exposure Methodology, p. 220

Inhaled product =

Inhalation rate x number of application/day x spray duration (min.) / 60 min. x indicative value for inhalation

Inhaled active substance =

inhaled product x percent of a.s. in the b.p.

Particle size distribution will determine the respirable fraction of the product released. Regarding the cut-off value for respirable droplet size, different sources are available. The BPR guidance III part B states that particles below 15 µm may reach the alveolar region of the respiratory tract. According to the Biocides Human Health Exposure Methodology, particles larger than 20 µm are all non-respirable and particles smaller than 5 µm are respirable for about 35 %. The draft Proposal for harmonising the assessment of human exposure to repellents (PT19) states that in general, the cut-off for the respirable fraction is 10 µm, and refers to ConsExpo 4.1 for the assessment of inhalation exposure. In ConsExpo 4.1, the default cut-off for the respirable fraction has been set at 15 µm. For the present assessment, a cut-off value of 15 µm for the respirable fraction has been chosen.

The applicant provided a study for the distribution of particles and their size. 11.21 %(V) of the released biocidal product has a diameter below 15.81 µm(V). The rest is regarded as non-respirable and is assumed to be taken in orally.

Inhalation systemic exposure:

11.21 % x inhaled a.s. x inhalation absorption / body weight

Oral systemic exposure:

88.79 % x inhaled a.s. x oral absorption / body weight

	Parameters	Value
For All categories	Inhalation absorption ¹	100%
	Oral absorption ¹	100%
	% of active substance in biocidal product ¹	20%
	Indicative value for inhalation ²	10.5 mg/m ³
	Spray duration ³	4 minutes
Tier 1- Adult	Number of application / day ¹	3
	Body weight ¹	60 kg
	Respiration rate [m ³ /air/hour] ¹	1.25 m ³ /h
Tier 1- Child 6 to < 12 years old	Number of application / day ¹	2
	Body weight ¹	23.9 kg
	Respiration rate [m ³ /air/hour] ¹	1.32 m ³ /h
Tier 1- Child 2 to < 6 years old	Number of application / day ¹	2
	Body weight ¹	15.6 kg
	Respiration rate [m ³ /air/hour] ¹	1.26 m ³ /h
Tier 1- Toddler	Number of application / day ¹	1

	Body weight ¹	10 kg
	Respiration rate [m ³ /air/hour] ¹	1.26 m ³ /h
Tier 1- Infant	Number of application / day ¹	1
	Body weight ¹	8 kg
	Respiration rate [m ³ /air/hour] ¹	0.84 m ³ /h
Tier 2- Adult	Number of application / day ⁴	2
Tier 2- Child 6 to < 12 years old	Number of application / day ⁴	1
Tier 2- Child 2 to < 6 years old	Number of application / day ⁴	1
Tier 3- Adult	Number of application / day ⁴	1

¹ General information, see justification above

² Model used: "Consumer spraying and dusting model 2 - Hand-held trigger spray" Biocide Human Health Exposure Methodology, p. 220

³ CAR of IR3535® (expert judgement)

⁴ Limitation of the exposure

Calculations for scenario 2

Summary table: estimated exposure for Inhalation Primary exposure			
Exposure scenario	Tier/PPE	Estimated inhalation uptake	Estimated oral uptake
Scenario 2 – ADULT 3 applications/day	Tier 1 / no PPE	0.000981 mg/kg bw	0.00777 mg/kg bw
Scenario 2 – CHILD (6-12) 2 applications/day	Tier 1 / no PPE	0.00173 mg/kg bw	0.0137 mg/kg bw
Scenario 2 – CHILD (2-6) 2 applications/day	Tier 1 / no PPE	0.00253 mg/kg bw	0.0201 mg/kg bw
Scenario 2 – TODDLER 1 application/day	Tier 1 / no PPE	0.00198 mg/kg bw	0.0157 mg/kg bw
Scenario 2 – INFANT 1 application/day	Tier 1 / no PPE	0.00165 mg/kg bw	0.0131 mg/kg bw
Scenario 2 – ADULT 2 applications/day	Tier 2 / no PPE	0.000654 mg/kg bw	0.0052 mg/kg bw
Scenario 2 – CHILD (6-12) 1 application/day	Tier 2 / no PPE	0.000867 mg/kg bw	0.0069 mg/kg bw
Scenario 2 – CHILD (2-6) 1 application/day	Tier 2 / no PPE	0.000127 mg/kg bw	0.0100 mg/kg bw
Scenario 2 – ADULT 1 application/day	Tier 3 / no PPE	0.000327 mg/kg bw	0.0026 mg/kg bw

Scenario 3: Secondary exposure (indirect exposure as a result of use): Hand-mouth transfer reverse reference scenario (oral exposure)

Description of Scenario 3		
<p>This scenario is based on the one available in the CAR of IR3535[®]. It has been updated with the document : Biocide Human Health Exposure Methodology (Oct 2015).</p>		
<p>Hand to mouth transfer might be possible for small children. However this scenario is not considered to be a significant route of exposure because of bad palatability (bitterness) preventing repeated mouthing by small children and you may not apply to children's hand. At TM IV 2010, it was agreed to develop the scenario "hand-mouth transfer" consistently with the DEET dossier evaluated by SE and to be discussed with HEEG and TM agreed not to sum up the two routes (oral and dermal) in small children. Reverse reference scenario is included to show how much IR3535[®] anyone can be exposed to, after oral exposure without exceeding reference dose (AEL for IR3535[®] is 5 mg/kg bw/d).</p>		
<p>External dermal amount of a.s. per application: Amount of b.p./application x percent of a.s. in b.p. / body weight</p>		
<p>Oral systemic exposure via hand-mouth transfer is: External dermal amount of a.s. per application x Factor for oral intake by hand-mouth transfer x oral absorption</p>		
<p>Number of time of application b.p. before exceeding the AEL via hand-mouth transfer : AEL / Oral systemic exposure via hand-mouth transfer</p>		
	Parameters	Value
For All categories	Oral absorption ¹	100 %
	% of active substance in biocidal product ¹	20 %
Tier 1- Adult	Factor for oral intake by hand-mouth transfer ²	4 %
	Body weight ¹	60 kg
	Amount of biocidal product/ application ¹	6.12 g
Tier 1- Child 6 to < 12 years old	Factor for oral intake by hand-mouth transfer ²	8 %
	Body weight ¹	23.9 kg
	Amount of biocidal product/ application ¹	3.39 g
Tier 1- Child 2 to < 6 years old	Factor for oral intake by hand-mouth transfer ²	8 %
	Body weight ¹	15.6 kg
	Amount of biocidal product/ application ¹	2.51 g
Tier 1- Toddler	Factor for oral intake by hand-mouth transfer ²	8 %
	Body weight ¹	10 kg
	Amount of biocidal product/ application ¹	1.77 g
Tier 1- Infant	Factor for oral intake by hand-mouth transfer ²	8 %
	Body weight ¹	8 kg
	Amount of biocidal product/ application ¹	1.51 g

¹ General information, see justification above

² 4% is the factor of the total treated body surface (Head, hands, arms, legs and feet) reported to the surface area of the fingers. 8% is the factor of the total treated body surface (Head, hands, arms, legs and feet) reported to

the surface area of the hands. They are default values currently discuss for a harmonisation of human exposure scenarios for PT19.

Calculations for scenario 3

Summary table: estimated exposure for Hand-mouth transfer reverse reference scenario (oral exposure)		
Exposure scenario	Tier/PPE	Calculated exposure to IR3535®
Scenario 3 – ADULT	Tier 1 / no PPE	Adult up to 6.13 applications
Scenario 3 – CHILD (6-12)	Tier 1 / no PPE	Child (6-12) up to 2.20 applications
Scenario 3 – CHILD (2-6)	Tier 1 / no PPE	Child (2-6) up to 1.94 applications
Scenario 3 – TODDLER	Tier 1 / no PPE	Toddler up to 1.77 applications
Scenario 3 – INFANT	Tier 1 / no PPE	Infant up to 1.65 applications

Scenario 4: Parent treating two children and himself/herself (spraying) (combined inhalative and oral exposure)

Description of Scenario 4		
Worst case: a parent applying (spraying) the product on two children and herself/himself		
Model used: it's the same model than the one used to do the scenario 2.		
Remark: the secondary dermal exposure were not assessed. It is covered by the primary dermal use exposure of the adult. The product would probably be rubbing on the child skin and the layer will not exceed the amount the adult will put on himself. So, BE has decided to follow the CAR which supposes that the dermal secondary exposure will be covered by the primary dermal exposure. Only inhalation exposure is relevant in this case.		
	Parameters	Value
For All categories	Inhalation absorption ¹	100 %
	Oral absorption ¹	100 %
	% of active substance in biocidal product ¹	20 %
	Indicative value for inhalation ²	10.5 mg/m ³
	Body weight ¹	60 kg
	Respiration rate [m ³ /air/hour] ¹	1.25 m ³ /h
	Spray duration ³	4 minutes
Tier 1- Adult	Number of application / day ¹	7 (3 appl/d for adult and 2 appl/d for each of the 2 children)

¹ General information, see justification above

² Model used: "Consumer spraying and dusting model 2 - Hand-held trigger spray" Biocide Human Health Exposure Methodology, p. 220

³ CAR of IR3535® (expert judgement)

Calculations for scenario 4

Summary table: estimated exposure for treating two children and himself/herself				
Exposure scenario	Tier/PPE	Estimated inhalation uptake	Estimated oral uptake	Estimated total uptake
Scenario 4 – ADULT (2 appl/child and 3 appl/himself)	Tier 1 / no PPE	0.00229 mg/kg bw	0.0181 mg/kg bw	0.0204 mg/kg bw

Scenario 5: Inhalation of volatilised residues after application (inhalative exposure)

Description of Scenario 5		
<p>This scenario is not based on the one available in the CAR of IR3535® because it's has been demonstrated that the SVC could exceed 1% in a number of cases. Considering HEEG opinion 13 (Assessment of Inhalation Exposure of Volatilized Biocide Active Substance), the inhalation of volatilised residues after application has to be taken into account for this product.</p> <p>The scenario is based on ConsExpo : inhalation of vapour, instantaneous release as a worst case and based on the document: Biocide Human Health Exposure Methodology (Oct 2015).</p> <p>Inhalation of volatilized residues after application is relevant considering the HEEG opinion on Assessment of Inhalation Exposure of Volatilized Biocide Active Substance:</p> $\frac{0.328 \times 215.29 \times 0.15}{5} = 2.12$ <p>The result of this equation is superior to 1 which means that the inhalation exposure couldn't be considered as negligible. So this exposure was assessed using ConsExpo – exposure to vapour – instantaneous release.</p> <p>General inputs to the model : Exposure duration: 24 hours (all day) Product amount: calculated dependent of the amount applied per day and per age categories Weight fraction compound: 20% (biocidal product information) Room volume: 20m³ (default value of ConsExpo) Ventilation rate: 0.6 /h (default value of ConsExpo)</p> <p>Vapour pressure: 0.15 Pa (at 20 °C) (active substance information) Molecular weight: 215.29 g/mol (active substance information) Temperature : 25°C (ambient temperature)</p>		
	Parameters	Value
Tier 1- Adult	Product amount ¹	6.12 g
	Body weight ²	60 kg
	Respiration rate [m ³ /air/hour] ²	1.25 m ³ /h
Tier 1- Child 6 to < 12 years old	Product amount ¹	3.39 g
	Body weight ²	23.9 kg
	Respiration rate [m ³ /air/hour] ²	1.32 m ³ /h
Tier 1- Child 2 to < 6 years old	Product amount ¹	2.51 g
	Body weight ²	15.6 kg
	Respiration rate [m ³ /air/hour] ²	1.26 m ³ /h
Tier 1- Toddler	Product amount ¹	1.77 g
	Body weight ²	10 kg
	Respiration rate [m ³ /air/hour] ²	1.26 m ³ /h
Tier 1- Infant	Product amount ¹	1.51 g
	Body weight ²	8 kg
	Respiration rate [m ³ /air/hour] ²	0.84 m ³ /h

- ¹ According the primary exposure, only one application per day can be authorized. Therefore, the product amount corresponds to 1 application/day.
- ² General information, see justification above

Calculations for scenario 5

Summary table: estimated exposure for inhalation of volatilised residues after application (inhalative exposure)		
Exposure scenario	Tier/PPE	Estimated inhalation uptake of volatilised residues after application
Scenario 5 – ADULT	Tier 1 / no PPE	2.12 mg/kg bw/day
Scenario 5 – CHILD (6-12)	Tier 1 / no PPE	3.12 mg/kg bw/day
Scenario 5 – CHILD (2-6)	Tier 1 / no PPE	3.37 mg/kg bw/day
Scenario 5 – TODDLER	Tier 1 / no PPE	3.71 mg/kg bw/day
Scenario 5 – INFANT	Tier 1 / no PPE	2.64 mg/kg bw/day

Combined scenarios : Total primary exposure, combination of scenario 1 and 2

Summary table: estimated exposure for combined scenarios 1+2					
Exposure scenario	Tier / PPE	Estimated dermal uptake [mg/kg bw/day]	Estimated inhalation uptake [mg/kg bw]	Estimated oral uptake [mg/kg bw]	Estimated total acute uptake for primary use [mg/kg bw]
Scenario 1+2 – ADULT 3 applications/day	Tier 1 / no PPE	8.56	0.000981	0.00777	8.57
Scenario 1+2 – CHILD (6-12) 2 applications/day	Tier 1 / no PPE	7.94	0.00173	0.0137	7.96
Scenario 1+2 – CHILD (2-6) 2 applications/day	Tier 1 / no PPE	8.99	0.00253	0.0201	9.02
Scenario 1+2 – TODDLER 1 application/day	Tier 1 / no PPE	4.95	0.00198	0.0157	4.97
Scenario 1+2 – INFANT 1 application/day	Tier 1 / no PPE	5.29	0.00165	0.0131	5.30
Scenario 1+2 – ADULT 2 applications/day	Tier 2 / no PPE	5.71	0.000654	0.0052	5.71
Scenario 1+2 – CHILD (6-12) 1 application/day	Tier 2 / no PPE	3.97	0.000867	0.0069	3.98
Scenario 1+2 – CHILD (2-6) 1 application/day	Tier 2 / no PPE	4.50	0.000127	0.0100	4.51
Scenario 1+2 – ADULT 1 application/day	Tier 3 / no PPE	2.85	0.000327	0.0026	2.86

The exposure of inhalation of volatilized residues after application and the combined inhalative and oral exposure of a parent treating two children are negligible compared to primary (dermal) exposure.

(VI) Exposure of the general public

Exposure of the general public is covered by the secondary exposure of non-professional.

(VII) Monitoring data

Not applicable.

(VIII) Dietary exposure

Considering the scenario 3 (hand to mouth transfer), considering that the amount in scenario 3 will be superior to the amount on the fingers of the hands (possible contact surface for transfer of residue to food) and finally considering that the biocidal product is not used for and/or during food production, or in rooms where food is produced processed or stored, the dietary risk would be covered by the scenario 3.

However, Belgium is of advice that the restriction measures (Wash hands thoroughly after handling., do not use on children's hands) must stay to avoid any misuse of the product.

(IX) Exposure associated with production, formulation and disposal of the biocidal product

In modern formulation plants typically automated equipment is used to add the formulation ingredients and to fill the formulated product into the respective vessels (closed systems). The workers (trained professionals) usually wear personal protective equipment (e.g. gloves). Thus the exposure can occur during the mixing and loading and have been calculated as a worst case.

Scenario 6 : Mixing and Loading model – worst case for the production, formulation and disposal of the biocidal product

Description of Scenario 6		
<p>For a worst case situation, it was estimated that the more sustainable model for industrial exposure production, formulation and disposal is : RISKOFDERM Dermal model (loading liquid, automated or semi-automated) from HEEG opinion 1 (2008).</p> <p>Dermal exposure via clothing: default potential exposure rates on clothing x Purity of the active substance x Duration of task x Number of events per day (x (1-Factor of protection for clothing))</p> <p>Dermal exposure via hands: default potential exposure rates on hands x Purity of the active substance x Duration of task x Number of events per day (x (1-Factor of protection for gloves))</p> <p>Dermal systemic exposure: (Dermal exposure via clothing + Dermal exposure via hands) x percent of dermal absorption / body weight</p> <p>Inhalation exposure: Inhalation is no relevant for this model and is not taken into account</p> <p>Systemic exposure: Dermal systemic exposure + 0 (inhalation exposure n.r.)</p>		
	Parameters¹	Value
Tier 1	Purity of the active substance ¹	99 %
	Dermal absorption ¹	50 %
	default potential exposure rates on clothing ²	101 mg/min
	default potential exposure rates on hand ²	2.02 mg/min
	default potential exposure rates for inhalation ²	n.r. mg/m ³ (and the substance has a low vapour pressure)
	Bodyweight ³	60 kg
	Number of events per day	1/day
	Duration of task	10 min
Tier 2	Factor of protection for Uncoated cotton overall ³	75 %
Tier 3	Factor of protection for gloves ³	90 %

¹ CAR (doc IIA)

General information, see justification above

² RISKOFDERM Dermal model: loading liquid, automated or semi-automated (HEEG opinion 1, 2008)

³ Biocide Human Health Exposure Methodology (Oct 2015)

Calculations for Scenario 6

Summary table: systemic exposure associated with production, formulation, and disposal					
Exposure scenario	Tier/PPE	Estimated inhalation uptake	Estimated dermal uptake [mg/kg bw/d]	Estimated oral uptake	Estimated total uptake [mg/kg bw/d]
Scenario 6	Tier 1/ no PPE	n.r.	8.5	n.r.	8.5
Scenario 6	Tier 2/ Uncoated cotton coverall	n.r.	2.25	n.r.	2.25
Scenario 6	Tier 3/ Uncoated cotton coverall and gloves	n.r.	2.1	n.r.	2.1

(X) Aggregated exposure

Not applicable.

(XI) Summary of exposure assessment

Scenarios and values to be used in risk assessment			
Scenario number	Exposed group (e.g. professionals, non-professionals, bystanders)	Tier/PPE	Estimated total uptake
1.	Non-professionals, adult	Tier 1, no PPE, dermal, 3 applications/day	8.56 mg/kg bw/day
	Non-professionals, child (6-12)	Tier 1, no PPE, dermal, 2 applications/day	7.94 mg/kg bw/day
	Non-professionals, child (2-6)	Tier 1, no PPE, dermal, 2 applications/day	8.99 mg/kg bw/day
	Non-professionals, toddler	Tier 1, no PPE, dermal, 1 application/day	4.95 mg/kg bw/day
	Non-professionals, infant	Tier 1, no PPE, dermal, 1 application/day	5.29 mg/kg bw/day
	Non-professionals, adult	Tier 2, no PPE, dermal, 2 applications/day	5.71 mg/kg bw/day
	Non-professionals, child (6-12)	Tier 2, no PPE, dermal, 1 application/day	3.97 mg/kg bw/day
	Non-professionals, child (2-6)	Tier 2, no PPE, dermal, 1 application/day	4.50 mg/kg bw/day
	Non-professionals, adult	Tier 3, no PPE, dermal, 1 application/day	2.85 mg/kg bw/day

2.	Non-professionals, adult	Tier 1, no PPE, inhalation, 3 applications/day	0.00875 mg/kg bw
	Non-professionals, child (6-12)	Tier 1, no PPE, inhalation, 2 applications/day	0.015646 mg/kg bw
	Non-professionals, child (2-6)	Tier 1, no PPE, inhalation, 2 applications/day	0.022615 mg/kg bw
	Non-professionals, toddler	Tier 1, no PPE, inhalation, 1 application/day	0.01764 mg/kg bw
	Non-professionals, infant	Tier 1, no PPE, inhalation, 1 application/day	0.0147 mg/kg bw
	Non-professionals, adult	Tier 2, no PPE, inhalation, 2 applications/day	0.005833 mg/kg bw
	Non-professionals, child (6-12)	Tier 2, no PPE, inhalation, 1 application/day	0.007732 mg/kg bw
	Non-professionals, child (2-6)	Tier 2, no PPE, inhalation, 1 application/day	0.011308 mg/kg bw
	Non-professionals, adult	Tier 3, no PPE, inhalation, 1 application/day	0.002917 mg/kg bw
3.	Non-professionals, adult	Tier 1, no PPE, Hand-mouth transfer reverse reference scenario, oral	Up to 6.13 applications
	Non-professionals, child (6-12)	Tier 1, no PPE, Hand-mouth transfer reverse reference scenario, oral	Up to 2.20 applications
	Non-professionals, child (2-6)	Tier 1, no PPE, Hand-mouth transfer reverse reference scenario, oral	Up to 1.94 applications
	Non-professionals, toddler	Tier 1, no PPE, Hand-mouth transfer reverse reference scenario, oral	Up to 1.77 applications
	Non-professionals, infant	Tier 1, no PPE, Hand-mouth transfer reverse reference scenario, oral	Up to 1.65 applications
4.	Non-professionals, adult	Tier 1, no PPE, inhal+oral, 7 appl/d	0.0204 mg/kg bw
5.	Non-professionals, adult	Tier 1 / no PPE	2.12 mg/kg bw/day
	Non-professionals, child (6-12)	Tier 1 / no PPE	3.12 mg/kg bw/day
	Non-professionals, child (2-6)	Tier 1 / no PPE	3.37 mg/kg bw/day
	Non-professionals, toddler	Tier 1 / no PPE	3.71 mg/kg bw/day
	Non-professionals, infant	Tier 1 / no PPE	2.64 mg/kg bw/day
6.	Professionals	Tier 1 / no PPE	8.5 mg/kg bw/d
	Professionals	Tier 2/ Uncoated cotton coverall	2.25 mg/kg bw/d
	Professionals	Tier 3/ Uncoated cotton coverall and gloves	2.1 mg/kg bw/d

3.2.7.3 Risk characterisation for human health

Reference values to be used in Risk Characterisation

Reference	Study	NOAEL (LOAEL)	AF ¹	Correction for oral absorption	Value
AELshort-term	Rabbit, oral, 28-days toxicity study Rabbit, oral, developmental study	500 (1500) mg/kg bw/d 300 (600) mg/kg bw/d	100	100%	5 mg/kg bw/d
AELmedium-term	Rabbit, oral, 28-days toxicity study Rabbit, oral, developmental study	500 (1500) mg/kg bw/d 300 (600) mg/kg bw/d	100	100%	5 mg/kg bw/d
AELlong-term	Rabbit, oral, 28-days toxicity study Rabbit, oral, developmental study	500 (1500) mg/kg bw/d 300 (600) mg/kg bw/d	100	100%	5 mg/kg bw/d (not applicable here, maximum number of applications is 28 days per year)
ARfD	n.a.	n.a.			not applicable, no residues in food or feed occur
ADI	n.a.	n.a.			not applicable, no residues in food or feed occur

¹ reason for assessment factor: factor 10 for both intra-species and interspecies differences. No extrapolation factor for duration is needed, as the overall NOAEL is derived from a repeated 28d-oral toxicity study and a teratogenicity study.

(I) Risk for industrial usersSystemic effects

Task/ Scenario	Tier	Systemic NOAEL mg/kg bw/d	AEL mg/kg bw/d	Estimated uptake mg/kg bw/d	Estimated uptake/ AEL (%)	Acceptable (yes/no)
Scenario 6, mixing & loading, professional	1	500 mg/kg bw/d	5 mg/kg bw/d	8.5 mg/kg bw/d	170%	no
Scenario 6, mixing & loading, professional	2	500 mg/kg bw/d	5 mg/kg bw/d	2.25 mg/kg bw/d	45%	yes
Scenario 6, mixing & loading, professional	3	500 mg/kg bw/d	5 mg/kg bw/d	2.1 mg/kg bw/d	42%	yes

Combined scenarios

Scenarios combined	Tier	Systemic NOAEL mg/kg bw/d	AEL mg/kg bw/d	Estimated uptake mg/kg bw/d	Estimated uptake/ AEL (%)	Acceptable (yes/no)
n.a.						

Local effects

The biocidal product is classified as eye damage/irritation cat 2, H319. However, appropriate risk mitigation measures are assumed to be taken by professionals during production, formulation and disposal. Consequently, there is no need to consider local effects separately.

Conclusion

There is no concern for professionals working with Insect Repellent Pump Spray IR3535® 20% during production, formulation and disposal when using appropriate PPE (minimum PPE required: uncoated cotton coverall).

(II) Risk for professional usersSystemic effects

Task/ Scenario	Tier	Systemic NOAEL mg/kg bw/d	AEL mg/kg bw/d	Estimated uptake mg/kg bw/d	Estimated uptake/ AEL (%)	Acceptable (yes/no)
n.a.						

Combined scenarios

Scenarios combined	Tier	Systemic NOAEL mg/kg bw/d	AEL mg/kg bw/d	Estimated uptake mg/kg bw/d	Estimated uptake/ AEL (%)	Acceptable (yes/no)
n.a.						

Local effects

n.a.

Conclusion

n.a.

(III) Risk for non-professional usersSystemic effects

Task/ Scenario	Tier	Systemic NOAEL [mg/kg bw/d]	AEL [mg/kg bw/d]	Estimated Uptake [mg/kg bw/d]	Estimated uptake/ AEL (%)	Acceptable (yes/no)
Scenario 1, dermal, adult	1	500	5	8.56	171.28	No
Scenario 1, dermal, child (6- 12)	1	500	5	7.94	158.87	No
Scenario 1, dermal, child (2-6)	1	500	5	8.99	179.90	No
Scenario 1, dermal, toddler	1	500	5	4.95	99.05	Yes
Scenario 1, dermal, infant	1	500	5	5.29	105.76	No
Scenario 1, dermal, adult	2	500	5	5.71	114.19	No
Scenario 1, dermal, child (6- 12)	2	500	5	3.97	79.43	Yes
Scenario 1, dermal, child (2-6)	2	500	5	4.50	89.95	Yes
Scenario 1, dermal, adult	3	500	5	2.85	57.09	Yes
Scenario 2, inhal +oral, adult	1	500	5	0.00875	0.175	Yes
Scenario 2, inhal +oral, child (6-12)	1	500	5	0.015646	0.31	Yes
Scenario 2, inhal +oral, child (2-6)	1	500	5	0.022615	0.45	Yes
Scenario 2, inhal +oral, toddler	1	500	5	0.01764	0.35	Yes
Scenario 2, inhal +oral, infant	1	500	5	0.0147	0.29	Yes
Scenario 2, inhal +oral, adult	2	500	5	0.005833	0.12	Yes
Scenario 2, inhal +oral, child (6-12)	2	500	5	0.007732	0.15	Yes
Scenario 2, inhal +oral, child (2-6)	2	500	5	0.011308	0.22	Yes
Scenario 2, inhal +oral, adult	3	500	5	0.002917	0.06	Yes
Scenario 3, hand- mouth transfer, adult	1	500	5	Up to 6.13 applications	n.a.	Reverse reference scenario
Scenario 3, hand- mouth transfer, child (6-12)	1	500	5	Up to 2.20 applications	n.a.	Reverse reference scenario
Scenario 3, hand- mouth transfer, child (2-6)	1	500	5	Up to 1.94 applications	n.a.	Reverse reference scenario
Scenario 3, hand- mouth transfer, toddler	1	500	5	Up to 1.77 applications	n.a.	Reverse reference scenario

Scenario 3, hand-mouth transfer, infant	1	500	5	Up to 1.65 applications	n.a.	Reverse reference scenario
Scenario 4, inhal+oral, adult	1	500	5	0.0204	0.4	Yes
Scenario 5, inhal, adult	1	500	5	2.12	42.4	Yes
Scenario 5, inhal, child	1	500	5	3.12	62.4	Yes
Scenario 5, inhal, child	1	500	5	3.37	67.4	Yes
Scenario 5, inhal, toddler	1	500	5	3.71	74.2	Yes
Scenario 5, inhal, infant	1	500	5	2.64	52.8	Yes

Combined scenarios

Scenarios combined	Tier	Systemic NOAEL [mg/kg bw/d]	AEL [mg/kg bw/d]	Estimated uptake [mg/kg bw]	Estimated uptake/AEL (%)	Acceptable (yes/no)
Scenario 1+2, adult, 3 appl/d	1	500	5	8.57	171.45	No
Scenario 1+2, child (6-12), 2 appl/d	1	500	5	7.96	159.18	No
Scenario 1+2, child (2-6), 2 appl/d	1	500	5	9.02	180.36	No
Scenario 1+2, toddler, 1 appl/d	1	500	5	4.97	99.40	Yes
Scenario 1+2, infant, 1 appl/d	1	500	5	5.30	106.05	No
Scenario 1+2, adult, 2 appl/d	2	500	5	5.71	114.30	No
Scenario 1+2, child (6-12), 1 appl/d	2	500	5	3.98	79.59	Yes
Scenario 1+2, child (2-6), 1 appl/d	2	500	5	4.51	90.18	Yes
Scenario 1+2, adult, 1 appl/d	3	500	5	2.86	57.15	Yes

Local effects

The biocidal product is classified as eye damage/irritation cat 2, H319. However, appropriate risk mitigation measures will be imposed and taken up on the label: 'Do not spray into the eyes or apply to eye area. An adult should apply the product to children below 12 years of age. Do not use on children's hands.' Consequently, there is no need to consider local effects separately.

Conclusion

Safe uses are identified for this product, Insect Repellent Pump Spray IR3535® 20% :

- for adult, children and toddler when the product is applied **once per day**.
- There is **no safe use for infants**. The product should not be applied on child below 1 year old.

There is no concern for indirect secondary exposure for adults, children and infants from the use of the biocidal product as a Repellent Subtype PT19.01. Exposure via hand-to-mouth transfer is of minor concern when the product is used as intended (not to be applied to children's hands), and inhalation of volatilized residues after application is limited. Secondary exposure for a parent applying (spraying) the product on children and herself/himself is minor compared to primary dermal exposure.

Proper use, i.e. use in compliance with correct and complete conditions on the label, of Insect Repellent Pump Spray IR3535® 20% is considered safe for adults and children.

The following RMM are required:

- Use repellent safely. Always read the label and product information before use.
- Suitable only for children older than 1 year.
- Keep out of reach of children.
- Avoid breathing spray. Do not spray directly on the face.
- Use only outdoors or in a well-ventilated area.
- ONLY apply to uncovered parts of the face, hands, arms, legs and feet. Do not use under clothing.
- Mechanical protection (clothing, mosquito nets) is to be preferred at all times. Only for external use. Use only as directed.

In combination with the following instructions for use:

- Apply the product evenly onto exposed skin and distribute the applied spray liquid on the skin by hand. ONLY apply to uncovered parts of the body, limited to arms, hands, legs, feet and face.
- Do not spray directly on the face. For treatment of the face, spray the repellent solution onto the palm of the hand and distribute the solution over the skin of the face thereby taking care to protect the eyes. Do not spray into the eyes or apply to eye area.
- An adult should apply the product to children below 12 years of age. Do not use on children's hands.
- Do not apply over cuts, wounds, freshly shaven or irritated skin. Do not use under clothing. Only for external use.
- Only children older than 1 year can use this product. Caution must be taken when using these products on children. Use products very responsibly. Mechanical protection (clothing, mosquito nets) is to be preferred at all times.
- Avoid contact with synthetic materials. Synthetic materials should be protected during spraying.
- Applying sun care products or cosmetic formulations after repellent use will decrease the efficacy of the repellent considerably.
- The product is not intended for use on animals/pets.

(IV) Risk for the general publicSystemic effects

Task/ Scenario	Tier	Systemic NOAEL mg/kg bw/d	AEL mg/kg bw/d	Estimated uptake mg/kg bw/d	Estimated uptake/ AEL (%)	Acceptable (yes/no)
n.a.						

Combined scenarios

Scenarios combined	Tier	Systemic NOAEL mg/kg bw/d	AEL mg/kg bw/d	Estimated uptake mg/kg bw/d	Estimated uptake/ AEL (%)	Acceptable (yes/no)
n.a.						

Local effects

n.a.

Conclusion

n.a.

(V) Risk for consumers via residues in food

Not applicable.

(VI) Risk characterisation from combined exposure to several active substances or substances of concern within a biocidal product

Not applicable.

3.2.8 Risk assessment for animal health

Not applicable.

3.2.9 Risk assessment for the environment

For the product Insect Repellent Pump Spray IR3535[®] 20 % no new studies or additional information for the environment have been provided. The active substance contained in this product is the same as evaluated in the CAR for IR3535[®] and therefore no new data/information on the active substance is required.

The composition of the representative product from the CAR is not identical to that of Insect Repellent Pump Spray IR3535[®] 20 %. However, the intended use is identical as well as the amount of active substance in both products. Only the active substance is of relevance for the environmental exposure assessment of this product.

3.2.9.1 Effects assessment on the environment

All data used for the effect assessment of Insect Repellent Pump Spray IR3535[®] 20% is based on the available information on the active substance IR3535[®], such as it is presented in its respective CAR.

No new data relevant for the environmental evaluation, nor on the product, nor on the active substance, have been submitted. Apart from the active substance, the product does not contain any formulants that are of ecotoxicological concern.

Following the referral conclusions for this product, it has been decided that Ethanol should be considered as a substance of concern, since it is responsible for the classification of the biocidal product as a flammable liquid.

However, from an ecotoxicological point of view, ethanol is not considered relevant. Based on its harmonized classification, ethanol is not classified for any environmental hazards. Therefore, ethanol was not considered during the environmental risk assessment.

An overview of the environmental fate and behaviour for the active substance, taken from the EU CAR, is presented in the first two titles below.

Environmental fate and behavior of the active substance

IR3535[®] is used in insect repellents (PT19) that are applied on uncovered human skin. Products containing IR3535[®] will be used indoors and outdoors. However the main emission pathway to the environment is assumed to be indirect due to bathing and showering of treated people. Based on the physico-chemical properties it is expected that the emissions primarily will affect the aquatic compartment.

IR3535[®] is not readily biodegradable according to two screening tests, but in a Sewage Treatment Plant (STP) simulation test 99 % elimination was measured. In an aerobic water/sediment degradation study, IR3535[®] was shown to remain mainly in the water phase. There it was first rapidly degraded to its free acid, after which this metabolite ultimately degraded after a lag phase.

No photolysis was observed in water and hydrolysis only occurred slowly under alkaline conditions ($DT_{50} = 176.5$ h at 25 °C and pH 9 or 866.13 h at 12 °C). Under acidic and neutral conditions IR3535[®] is hydrolytically stable.

The vapour pressure of IR3535[®] is low (0.15 Pa at 20 °C) which results in low exposure to the atmosphere. The half-life of IR3535[®] in air was calculated to be about 0.5482 days or 13.16 hours due to reaction with OH-radicals (24-hr day). Thus, accumulation of IR3535[®] in air and long range transport is unlikely.

IR3535[®] is a liquid at room temperature and the solubility in water is 70 g/L (at 20 °C). The log P_{ow} is 1.7 (at 23-24 °C) indicating that IR3535[®] has a low potential for bioaccumulation.

Based on the adsorption/desorption test a mean (arithmetic) K_{oc} form 475.25 L/kg was registered.

Effect assessment of the active substance

No toxic effects were observed during the acute toxicity studies on fish (*Brachydanio rerio*), *Daphnia magna* and algae (*Desmodesmus subspicatus*) ($LC_{50} > 100$ mg/L). Therefore IR3535[®] is considered as not toxic for the aquatic environment.

The effect on aerobic biological sewage treatment processes was assessed by determining inhibition of respiration of the micro-organisms present in activated sludge following 3 hours contact. No inhibitory effect on aquatic microbial activity was registered for IR3535[®] ($EC_{50} > 1000$ mg/L).

Long term aquatic tests were not required because no acute toxicity was observed for the aquatic environment and the substance is primarily emitted to the STP before reaching the aquatic environment. Besides the Sewage Treatment Plant (STP) simulation test showed an elimination of 99 % in the STP.

No marine species were tested based on the presence of studies performed on freshwater species, all suggesting low toxicity and because no major emissions to the marine environment are expected.

In the absence of any long-term toxicity endpoints and marine data, the TGD on Risk Assessment prescribes an assessment factor of 1000 for the freshwater environment and 10000 for the marine environment.

For the sediment compartment, there are also no toxicity data available. The $PNEC_{sediment}$ was calculated based on equilibrium partitioning method and $PNEC_{water}$.

No terrestrial toxicity tests were performed for IR3535[®]. Due to the method of application directly on the skin only limited and very local emissions to the soil are expected. IR3535[®] is not likely to become accumulated in the soil in large amounts. $PNEC_{soil}$ has been calculated based on the equilibrium partitioning method.

The physicochemical properties of IR3535[®] do not suggest that this substance will pose a risk to the atmospheric environment. Therefore no PNECs were calculated for this compartment.

The low BCF values suggest that IR3535[®] has a low bioaccumulation potential. Therefore the risk of secondary poisoning via ingestion of contaminated food (eg. earthworms or fish) by birds or mammals is also low and no avian dietary tests were required.

Summary of PNEC values for the active substance	
Compartment	PNEC value
$PNEC_{aquatic}$	> 0.1 mg/l
$PNEC_{sediment}$	> 1.11 mg/kg wwt
$PNEC_{micro-organisms (STP)}$	100 mg/l
$PNEC_{soil}$	> 0.85 mg/kg wwt

PNEC _{saltwater}	> 0.01 mg/l
PNEC _{marine-sediment}	> 0.111 mg/kg wwt

(I) Information relating to the ecotoxicity of the biocidal product which is sufficient to enable a decision to be made concerning the classification of the product is required

The product does not contain any substance at such a concentration that it has an effect on the environmental classification of the product. No additional information on the biocidal product is required.

Conclusion on the environmental classification and labelling of the product

Insect Repellent Pump Spray IR3535® 20% does not require any environmental classification or labelling.

(II) Further Ecotoxicological studies

The assessment of the active substance in the CAR showed that there is no concern for the aquatic and terrestrial environment and thus no further ecotoxicological studies are required according to the CAR.

For this particular product, there is no direct exposure to the environment and the product does not contain formulants other than the active substance that could be of ecotoxicological concern, thus the data on the active substance are sufficient for the evaluation of the ecotoxicological effects of the biocidal product.

(III) Effects on any other specific, non-target organisms (flora and fauna) believed to be at risk (ADS)

No further data is available.

(IV) Supervised trials to assess risks to non-target organisms under field conditions

The product is not in the form of bait or granules, so no such data is required.

(V) Studies on acceptance by ingestion of the biocidal product by any non-target organisms thought to be at risk

The product is not in the form of bait or granules, so no such data is required.

(VI) Secondary ecological effect e.g. when a large proportion of a specific habitat type is treated (ADS)

Not relevant.

(VII) Foreseeable routes of entry into the environment on the basis of the use envisaged

The foreseeable routes of entry into the environment have been described in the CAR for the active substance and are also valid for this product.

Direct release to soil is not considered relevant, whereas direct release to surface water (swimming lake scenario) is considered relevant, but was not yet assessed in the CAR due to the lack of an endorsed scenario.

Secondary release via wastewater and STP through showering and bathing is also a relevant route of emission.

(VIII) Further studies on fate and behaviour in the environment (ADS)

No new data was submitted or is required. Information on the active substance suffices for the environmental risk assessment of the product. Moreover, the product does not contain any other substances relevant for the environment apart from the active substance.

(IX) Leaching behaviour (ADS)

Not relevant.

(X) Testing for distribution and dissipation in soil (ADS)

Since there is no direct release to soil and the soil compartment is not envisioned as a compartment of interest in the evaluation of this product, none such additional data is submitted or required.

(XI) Testing for distribution and dissipation in water and sediment (ADS)

No new data was submitted or is required.

(XII) Testing for distribution and dissipation in air (ADS)

No new data was submitted or is required.

(XIII) If the biocidal product is to be sprayed near to surface waters then an overspray study may be required to assess risks to aquatic organisms or plants under field conditions (ADS)

No new data was submitted or is required.

(XIV) If the biocidal product is to be sprayed outside or if potential for large scale formation of dust is given then data on overspray behaviour may be required to assess risks to bees and non-target arthropods under field conditions (ADS)

No new data was submitted or is required.

3.2.9.2 Exposure assessment

Insect Repellent Pump Spray IR3535® 20% is not exactly the same product as the representative product in the CAR, however for all intends and purposes of an environmental exposure assessment it can be seen as the same. This is because the proposed use of the product and the amount of active substance in the product is identical to that presented the environmental exposure assessment of the CAR and the only component of the product possibly affecting the risk to the environment is the active substance itself.

However, since the finalisation of the CAR for IR3535® a new ESD for PT19 biocides has been endorsed and published, which contains scenarios which were not yet assessed during the evaluation of the active substance, such as direct emissions to surface water by swimmers, which is named as an element to be taken into account at product authorisation stage in the assessment report of the active substance.

Therefore the evaluation presented below will be based on this new ESD.

(I) General information

Assessed PT	PT 19
Assessed scenarios	Scenario 1: Removal via showering and bathing of humans (ESD PT19, May 2015, §3.1.4.1) Scenario 2: Release to surface water bodies via swimming (ESD PT19, May 2015, §3.1.4.2)
ESD(s) used	Emission Scenario Document for Product Type 19: Repellents and attractants, May 2015 (ECHA-15-B-10-EN)
Approach	Scenario 1: Average consumption Scenario 2: Average consumption
Distribution in the environment	Calculated based on TGD 2003
Groundwater simulation	Not applicable
Confidential Annexes	None
Life cycle steps assessed	Scenario 1: Showering & bathing <ul style="list-style-type: none"> • Production: No • Formulation: No • Use: Yes • Service life: No Scenario 2: Swimming <ul style="list-style-type: none"> • Production: No • Formulation: No • Use: Yes • Service life: No
Remarks	/

(II) Emission estimation

Scenario 1: Removal via showering and bathing

Consumption based scenario

For estimating the emission for products applied on human skin following showering or bathing one could either use a tonnage based scenario or a consumption based scenario.

Tonnage based approaches are mostly only appropriate for assessing an active substance for approval and not so much for the authorisation of biocidal products. Therefore only the consumption based approach is assessed here.

However, the tonnage based approach was calculated in the IR3535® CAR and can be consulted in the confidential annex of said CAR. Anyway when considering the break-even tonnage, the consumption based scenario is deemed to be the most appropriate scenario.

Amount of product per application ($Q_{form_{appl}}$)

The most important input parameter for the consumption based scenario is the amount of product that will be used per application ($Q_{form_{appl}}$). As a default value in the ESD 0.6 mg product/cm² skin is proposed.

However, the ESD also mentions that the value for $Q_{form_{appl}}$ must coincide with the efficacy of the product and must be adapted accordingly.

The validated efficacious dose for the product 'Insect Repellent Pump Spray IR3535 20%' is 0.67 mg product per cm² of skin. This value will be considered in the environmental risk assessment instead of the default value from the ESD.

$$Q_{form_{appl}} = 0.67 \text{ mg product/cm}^2 \text{ skin}$$

Number of applications per day (N_{appl})

Another important parameter is the number of applications per day (N_{appl}), which the ESD also links to the efficacy of the product.

The conclusion for efficacy of 'Insect Repellent Pump Spray IR3535 20%' is that the product will remain efficacious for 8 hours against mosquitoes, when used at the application rate of 0.67 mg/cm². Following the ESD Table 3-2, 2 applications per day will be used in the further assessment.

$$N_{appl} = 2 \text{ d}^{-1}$$

Treated area of human skin ($AREA_{skin}$)

Following the agreement of the ENV WG-V-2018 to harmonise the value for the treated skin area with that of the Human Health assessment, a value of 55% of the total body surface area will be applied.

$$AREA_{skin} = 9130 \text{ cm}^2$$

Input parameters for calculating the local emission				
Input	Nomenclature	Value	Unit	Remarks
<i>Scenario: Release of repellents used on human skin based on the average consumption</i>				
Number of inhabitants feeding one STP	N _{local}	10 000	cap	D
Active substance in product	(B) C _{formweight}	200	g/kg	(20 %)
Consumption per application	(D2) Q _{formappl}	0.67	mg/cm ²	(see above)
Number of applications per day	N _{appl}	2	d ⁻¹	(see above)
Treated area of human skin	AREA _{skin}	9130	cm ²	(see above)
Fraction released to air	F _{air}	0	[-]	D
Fraction dermally absorbed	F _{skin}	0	[-]	D

Fraction released to wastewater	Fwater	1	[-]	D
Fraction of inhabitants using a repellent product	Finh	0.2	[-]	D
Market share of repellent	Fpenetr	0.5	[-]	D
Specific density of the product	RHOform	1000	kg/m ³	D

Calculations for Scenario 1

→ B and D2

$$E_{local_{wastewater}} = N_{local} \times N_{appl} \times Q_{form_{appl}} \times AREA_{skin} \times C_{form_{weight}} \times F_{inh} \times F_{water} \times F_{penetr} \times 10^{-9}$$

Resulting local emission to relevant environmental compartments

Compartment	Local emission (E _{local_{compartment}}) [kg/d]	Remarks
Waste water	2.45	/

Scenario 2: Release to surface water bodies via swimming

In the assessment report for IR3535[®], in the paragraph on the elements to be taken into account when authorising products, it is mentioned that direct emissions to surface water by swimmers should be kept in mind and assessed. With this new scenario for the ESD for PT19, this requisite is taken into account.

Amount of product per application ($Q_{form_{appl}}$)

Similarly as with scenario 1, the most important input parameter for this scenario is the amount of product that will be used per application ($Q_{form_{appl}}$).

The same notes and thoughts can be applied as with scenario 1. Therefore, also here it is decided that the efficacious dose will be applied.

$$Q_{form_{appl}} = 0.67 \text{ mg product/cm}^2 \text{ skin}$$

Treated area of human skin ($AREA_{skin}$)

Concerning the body surface to which the product is applied ($AREA_{skin}$), according to the applicant the product should only be applied to the face, arms, hands and legs. However, when repellent products are used when swimming, one could assume the swimmer would apply it also to their feet and trunk. Therefore, for a worst case calculation, it is assumed the product is applied to the full body surface.

$$AREA_{skin} = 16600 \text{ cm}^2$$

Input parameters for calculating the local emission				
Input	Nomenclature	Value	Unit	Remarks
<i>Scenario: Release of repellents used on human skin due to swimming activities in surface water bodies</i>				
Daily number of swimmers	$N_{swimmer}$	1500	[-]	D
Fraction of swimmers using repellent product	F_{swim}	0.1	[-]	P (worstcase)
Number of applications per day	N_{appl}	1	d ⁻¹	D
Fraction released to surface water body	$F_{waterbody}$	1	[-]	D
Active substance in the product	(B) $C_{formweight}$	200	g/kg	(20%)
Consumption per application	(D2) $Q_{form_{appl}}$	0.67	mg/cm ²	(see above)
Treated area of human skin	$AREA_{skin}$	16600	cm ²	(see above)
Specific density of product	RHO_{form}	1000	kg/m ³	D

Intermediate calculation for Scenario 2

→ B and D2

$$E_{local_{water}} = N_{swimmer} \times N_{appl} \times Q_{form_{appl}} \times AREA_{skin} \times C_{formweight} \times F_{swim} \times F_{waterbody} \times 10^{-9}$$

Resulting local emission to relevant environmental compartments		
Compartment	Local emission ($E_{local_{compartment}}$) [kg/d]	Remarks
Surface water	0.334	/

Final calculation for scenario 2

In the intermediate calculation a local daily emission to the surface water body due to swimmers treated with the repellent, was calculated. In order to assess the impact of this emission on the aquatic life in this waterbody, the actual concentration in active substance in this waterbody should be calculated.

As a first TIER evaluation concentrations are calculated for emission periods of 1 day and 91 days, without taking into account possible degradation progresses, which represents the worst-case.

Input parameters for calculating surface water concentration				
Input	Nomenclature	Value	Unit	Remarks
<i>Scenario: Release of repellents used on human skin due to swimming activities in surface water bodies</i>				
Local emission to surface water body	$E_{local,water}$	0.334	kg/d	O (Intermediate calculation)
Volume of water body	$V_{waterbody}$	435 000	m ³	D
Number of emission days TIER 1	$T_{emission, 1d}$	1	d	D
Number of emission days TIER 2	$T_{emission, 91d}$	91	d	D
Number of emission events	$N_{emission, 91d}$	91	[-]	D

$$C_{local,water,1d} = \frac{E_{local,water} \times T_{emission,1d}}{V_{waterbody}}$$

$$C_{local,water,91d} = \frac{E_{local,water} \times T_{emission,91d}}{V_{waterbody}}$$

Resulting local concentrations in the waterbody		
Compartment	Local concentration ($C_{local,compartment}$) [kg/m ³]	Remarks
Surface water – after 1 day	7.67×10^{-7}	/
Surface water – after 91 days	6.98×10^{-5}	(without considering possible degradation)

(III) Fate and distribution in exposed environmental compartments

Scenario 1:

Applied product is removed from the body through showering or bathing. The wastewater from washing is then removed to the municipal waste water treatment plant, after which the effluent is emitted to the surface water where it can expose both fresh water and fresh water sediments.

Exposure to other compartments, such as soil and groundwater, is not considered relevant. The soil could be exposed through sludge application, but following the STP-distribution detailed in the third table below, sorption to sewage sludge is unlikely since IR3535 is almost completely degraded.

Scenario 2:

Applied product is removed from the body directly to the surface water through swimming, where it can expose both fresh water and fresh water sediments.

Exposure to other compartments is not considered relevant.

Identification of relevant receiving compartments based on the exposure pathway									
	Fresh-water	Freshwater sediment	Sea-water	Seawater sediment	STP	Air	Soil	Ground-water	Other
Scenario 1	yes	yes	no	no	yes	no	no	no	no
Scenario 2	yes	yes	no	no	no	no	no	no	no

Input parameters (only set values) for calculating the fate and distribution in the environment			
Input	Value	Unit	Remarks
Molecular weight	215.29	g/mol	
Melting point	-90	°C	
Boiling point	300	°C	
Vapour pressure (at 20 °C)	0.15	Pa	
Water solubility (at 20 °C)	70 000	mg/l	
Log Octanol/water partition coefficient	1.7	Log 10	
Organic carbon/water partition coefficient (Koc)	475.25	l/kg	
Henry's Law Constant (at 20 °C)	4.613x10 ⁻⁴	Pa.m ³ /mol	
Biodegradability	Not readily biodegradable		

In the CAR for IR3535®, calculations according to EUSES are available for the distribution in the STP, which in this case is only relevant for scenario 1. As a worst-case assessment the distribution presented in the CAR is taken over for the assumption that there is no degradation. As a TIER 2 evaluation, 99% degradation in STP is taken into consideration.

Calculated fate and distribution in the STP				
Compartment	Percentage [%]			Remarks
	Scenario 1 TIER 1	Scenario 1 TIER 2	Scenario 2	
Air	0	0	Not relevant	
Water	99	1		
Sludge	1	0		
Degraded in STP	0	99		

(IV) Calculated PEC values

Neither for scenario 1, nor for scenario 2, calculations were made for the sediment, since the $PNEC_{\text{sediment}}$ was determined through the EPM-method. This means that the risk assessment for water is applicable for the sediment as well.

As mentioned before, for the scenario 2, possible degradation in surface water is not taken into account as a worst-case evaluation.

Summary table on calculated PEC values			
		PEC_{STP}	PEC_{water}
		[mg/l]	[mg/l]
Scenario 1	TIER 1	1.21	0.121
	TIER 2	1.22×10^{-2}	1.22×10^{-3}
Scenario 2	Day 1	n/a	7.67×10^{-4}
	Day 91	n/a	6.98×10^{-2}

(V) Primary and secondary poisoning

a) Primary poisoning

Not applicable, since this product is a repellent and has no intention of killing.

b) Secondary poisoning

Not relevant, since no bioaccumulation is expected.

3.2.9.3 Risk characterisation

(I) Atmosphere

Conclusion:

Only negligible exposure to the atmosphere is expected and no threat to the atmosphere is expected.

(II) Sewage treatment plant (STP)

Summary table on calculated PEC/PNEC values		
		PEC/PNEC _{STP}
Scenario 1	TIER 1	1.21x10 ⁻²
	TIER 2	1.22x10 ⁻⁴
Scenario 2	Day 1	Not relevant
	Day 91	Not relevant

Conclusion:

No adverse effect for the STP is expected

(III) Aquatic compartment

Neither for scenario 1, nor for scenario 2, calculations were made for the sediment, since the PNEC_{sediment} was determined through the EPM-method. This means that the risk assessment for water is applicable for the sediment as well.

For the scenario 2, possible degradation in surface water is not taken into account as a worst-case evaluation.

Summary table on calculated PEC/PNEC values		
		PEC/PNEC _{water}
Scenario 1	TIER 1	1.21
	TIER 2	1.22x10 ⁻²
Scenario 2	Day 1	7.67x10 ⁻³
	Day 91	6.98x10 ⁻¹

For the scenario 1, when considering the worst-case assessment where no elimination from the STP is taken into account, then an adverse effect for the surface water is calculated. However when considering the TIER 2, where 99 % elimination from the STP is considered, no adverse effects are calculated.

For the scenario 2, no adverse effects are expected, neither at day 1 nor at day 91, without considering degradation in the surface water.

Conclusion:

No adverse effect for the aquatic compartment is expected

(IV) Terrestrial compartment

The terrestrial compartment is not considered a relevant receiving compartment (see point (III) above).

Exposure through sludge application is highly unlikely, since IR3535 almost completely degrades in the STP.

Conclusion

No adverse effects for the terrestrial compartment are expected

(V) Groundwater

Since no exposure of the terrestrial compartment is expected, it follows that neither exposure to the groundwater is expected.

Conclusion

No adverse effects for the groundwater are expected.

(VI) Primary and secondary poisoning

Primary poisoning is not applicable, since this product is a repellent and has no intention of killing.

Secondary poisoning is not relevant, since no bioaccumulation is expected.

(VII) Mixture toxicity

Not relevant, since the product does not contain other components other than the active substance that could give a risk to the environment.

3.2.10 Measures to protect man, animals and the environment

Please see §2.1.4 and §2.1.5 above.

3.2.11 Assessment of a combination of biocidal products

Not applicable

3.2.12 Comparative assessment

Not applicable

4 ANNEXES

4.1 LIST OF STUDIES FOR THE BIOCIDAL PRODUCT

Author(s)	Year	Title	Report No.	Owner Company	Report date
Meinerling M.	2009	EUS26-15 INSECT REPELLENT SPRAY - DETERMINATION OF THE STORAGE STABILITY AT AMBIENT TEMPERATURES	31232204	Merck KGaA	2009-05-27
Meinerling M., Fieseler A.	2016	Statement to IBACON project	-	-	2016-21-06
Fieseler A.	2015	MDA-A-197-01 Verum 1: Accelerated Storage Stability	98322204	Merck KGaA	2015-08-04
Meinerling M.	2007	EUS26-15 INSECT REPELLENT SPRAY - DETERMINATION OF THE ACCELERATED STORAGE STABILITY	31231204	Merck KGaA	2007-02-28
Fieseler A.	2011	Determination of the Relative Density of Pump Spray IR 3535® 20 %	63163182	Merck KGaA	2011-06-27
Meinerling M.	2011	Determination of the Low Temperature Stability of Pump Spray IR 3535® 20 %	63164204	Merck KGaA	2011-06-27
Fieseler A.	2011	Determination of the Flash Point of Pump Spray IR 3535® 20 %	63161189	Merck KGaA	2011-06-28
Batz B.	2016	Bestimmung der Tröpfchengrößenverteilung per Laserbeugung Merck Prüfauftrag vom 30.03.2016	2016_04_26	Merck KGaA	2016-04-26
Zur Lage J.	2016	IR3535_Ref Formulations surface tension visco_Reg.Aff	009093 - PM - PFC - RT	Merck KGaA	
Dornhagen J.	2011	FINAL REPORT (1st Original of 3) Pump Spray IR 3535® 20 % Batch No.: SM-0-1-1/090211 AUTO-IGNITION TEMPERATURE (LIQUIDS AND GASES) A.15	20110103.01	Merck KGaA	2011-07-04
Meinerling M.	2007	IR3535® - VALIDATION OF AN ANALYTICAL METHOD FOR THE DETERMINATION OF IR3535® AND ITS HYDROLYSIS PRODUCT IN DIFFERENT FORMULATIONS	31211101	Merck KGaA	2007-03-19
Carroll, S.P.	2006	"Test of Personal Insect Repellents: Study EMD 003.2 - Replacement for MRID 46979002 - Volume 11"	336-1918	Merck KGaA	2006-11-08
Carroll, S.P.	2006	"Test of Personal Insect Repellents: EMD 004.2 Replacement for MRID 46979004"	336-1919	Merck KGaA	2006-11-06
Dippel, C. and Dautel, H.	2006	"Evaluation of 6 products against the European Sheep Tick, Ixodes ricinus, on human volunteers according to the EPA guidelines"	336-1921	Merck KGaA	2006-04-27
Lüpkes, K.-H.	2011	"Repellent Efficacy of Six Repellent Formulations on Human Arms against Mosquitoes"	336-1922	Merck KGaA	2011-07-04
(a)	2006	Acute dermal irritation study of EUS26-15 Insect Repellent Spray in albino rabbits.		Merck KGaA	2006-09-15
(b)	2006	Acute Eye Irritation Study of EUS26-15 Insect Repellent Spray in albino rabbits.		Merck KGaA	2006-09-08

(c)	2006	Skin Sensitisation Study of EUS26-15 Insect Repellent Spray in albino guinea pigs (Modified Buehler Method).		Merck KGaA	2006-09-08
(d)	2006	Acute dermal toxicity study of EUS26-15 Insect Repellent Spray in albino rats.		Merck KGaA	2006-09-15

➤ **NA-MIC minor change application (2023)**

Author(s)	Year	Title	Report No.	Owner Company	Report date
Firseler A.	2022	Insect Repellent Pump Spray IR3535® 20% (EUS-26-15): Storage Stability at Ambient Temperature	152041228	Merck KGaA	2022-11-01

4.2 OUTPUT TABLES FROM EXPOSURE ASSESSMENT TOOLS

4.2.1 Human exposure calculations



PT19 - calculation table.xlsx

4.3 NEW INFORMATION ON THE ACTIVE SUBSTANCE

Not applicable.

4.4 RESIDUE BEHAVIOUR

Not applicable.

4.5 SUMMARIES OF THE EFFICACY STUDIES (B.5.10.1-XX)

Not relevant, IUCLID file available.

4.6 CONFIDENTIAL ANNEX

Yes, see separate document.

4.7 OTHER

Not applicable.